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1. Introduction 
1.1 The antibiotic resistance problem 
Bacteria are monocellular prokaryotic microorganisms. Compared to the eukaryotic cells, 
bacterial cells are characterized by an absence of organelles in the cytoplasm, the absence of a 
nucleus and the consequent presence of DNA in a free form. Bacteria can be defined more 
precisely observing their molecular characteristics, to strictly distinguish their domain from the 
ones of Archaea and Eucarya.[1]
Thanks to millions of years of adaptation bacteria can be found in many different environments 
on earth, from the common soil to less usual environments like acidic spring waters, depth soil 
and seas.[2] Moreover, bacteria can be found in our body[3] and especially in the gut, where their 
population can partially change depending on the diet:[4] some bacteria species can establish a 
commensal and/or symbiotic relationship with humans, influencing for examples their immune 
functions, as well as the processing of nutrients.[5]
Certain strains of bacteria can act as pathogens and caused the plethora of diseases which marked 
our history. Yersinia pestis was responsible for the big epidemy in the Middle age known as “black 
death”, which led to the death of 25 to 50% of the European population and was triggering many 
social and political changes, among others the start of the Secularization in Europe.[6]
Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, is one of the most 
widespread and persistent infectious diseases, which caused many victims in the previous 
centuries, and continue to be a lethal disease even nowadays, especially in the developing 
countries, with almost one third of human population supposedly being infected.[7] The memory 
of this disease in the occidental culture is still vivid in the mass culture and it plays an essential 
role in several books, movies, as well as theater’s plays and operas like the famous “La Traviata” 
of Giuseppe Verdi. Furthermore, during the 19th century, bacterial infections such as pneumonia, 
diarrhea and diphtheria represented the main causes of death.[8] Bacteria were also limiting the 
positive outcome of surgical operations, even after the introduction of antisepsis procedures, due 
to post­surgical infections.[9]
The discovery of penicillins in 1928 by Fleming[10] and of the sulfonamides in 1932 by Domagk[11]
made the extensive treatment of bacterial infections possible for the first time. This 
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revolutionized the medical field and significantly increased the human life expectancy. After 
World War II several classes of effective antibiotics were discovered, and a wave of optimism 
emerged between many physicians which can be adequately summarized by the presumable 
statement of the US Surgeon General William H. Stewart 
 “[it] is time to close the book on infectious diseases and declare the war against pestilence won.” 
Curiously, background research later showed that this sentence was never actually stated ­ on 
the contrary Stewart insisted to never underestimate the danger of infectious diseases.[12] The 
first appearance of antibiotic resistant bacteria in the hospitals was already documented in the 
years after the first use of sulfonamides and penicillin in Germany in the 1930s and in the United 
Kingdom in the 1940s.[13] Later on, the first multi­drug resistant strains (Escherichia coli and 
Salmonella species) were isolated in Africa during the 1950s and 60s.[14] Antibiotic resistance is 
an ancient phenomenon:[15] phylogenetic reconstruction highlights the rise of antibiotic 
resistance genes well before the production of antibiotics as pharmaceutical drugs.[16]
Furthermore genomic sequencing data acquired from several strains collected in a Mexican cave 
dated 4 million years, evidenced the presence of some strains resistant to up of 14 different 
commercially available antibiotics, highlighting how resistance phenomenon existed well before 
antibiotics were discovered and in an environment isolated from the anthropogenic impacts.[17]
The antibiotics resistance phenomenon has been accelerated by the excessive and/or 
inappropriate use of antibiotics.[18] In many countries worldwide, antibiotics can be purchased 
without medical prescription, can be prescribed without any diagnosis or confirmation on the 
ongoing bacterial infection and/or consumed for an ineffective period of time. Misbehaviors, both 
on the physicians and on the patients sides, led to the quick development of genetic resistance 
by the survived bacterial populations and to their diffusion in the environment.[19] The use of 
antibiotics in intensive breeding and aquaculture, not only as prevention, but also as growth 
promotion agents is a further source of serious concern, even though the risks that this practice 
bears are known since the 1960s.[20] In this way, antibiotics are assumed by healthy individuals 
through nutrition and furthermore are spread in the environment by animal dejections, altering 
the soil microbiota and favoring the development of antibiotics resistant strains. 
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Antimicrobial resistance can be acquired as result of chromosomal mutation or inductive 
expression of a latent chromosomal gene or transmitted by genetic exchange through 
transformation (the exchange of DNA), transduction (bacteriophage), or conjugation by plasmids 
(extrachromosomal DNA).[21] Particularly, bacteria can become immune to the effects of 
antibiotics in several ways,[22] for example, by modifying/reprogramming the target structures 
(proteins),[23] deactivating enzymatically the antibiotic[24] such in the case of the beta 
lactamase,[25] limiting the antibiotic penetration inside the cells[26] or increasing its efflux.[27]
Antibiotic resistance strains were isolated for many different bacterial species.[28] The gram­
positive methicillin­resistant Staphylococcus aureus, responsible for serious infections like 
pneumonia, infective endocarditis and bone/joint infections especially in hospitalized patients,[29]
is estimated to be responsible of 19.000 fatalities per year solely in the USA.[30,31] Additional 
antibiotics resistant strains which are commonly isolated in hospitals are Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Enterococcus faecalis, Clostridium difficile, and the above mentioned 
M. tuberculosis.[28,30] Particularly, gram­negative bacteria have the ability to quickly develop 
resistance to multiple antibiotics: in fact organisms can be isolated which are resistant to nearly 
all the available antibiotics.[19] Even some strains of the normally harmless E. coli showed 
ampicillin resistance increasing the difficulty of treatments.  
Antimicrobial resistant strains are becoming a serious plague for human health and, from the 
economic point on view, an heavy burden for many healthcare systems.[32] The occurrence of 
infections caused by antibiotic resistant bacteria is dramatically rising in the clinics all over the 
world.[33,34] As representative example, the incidence of P. aeruginosa with combined antibiotics 
resistance, i.e. resistant to at least three classes of commercial antibiotics, isolated in the 
European Union countries in 2016 is reported in Figure 1.1. It is clear how the antimicrobial 
resistance problem is generally spreading.[35]
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Figure 1.1. Incidence of P. aeruginosa with combined antibiotics resistance isolated in 2016 in the European 
Union.[35]
In “the review on antimicrobial resistance” O’Neill reported that 700.000 deaths every year are 
caused by antibacterial resistant strains.[36] Furthermore, considering the current behavior and 
attitude toward antibiotics, a vertiginous increase in fatalities caused by bacterial infections has 
been predicted: fatalities are expected to reach 10 million per year by 2050, exceeding the 
dimensions caused nowadays yearly by cancer.[36] The losses are huge also from an economical 
point of view. As example, the costs supported by the healthcare system only for methicillin­
resistant S. aureus infections is estimated in $3­4 billion per year in the USA,[31] while the total 
loss in household income due to resistant species is $35 billion yearly only in the USA.[37] The 
economic burden is so heavy that if serious measures are not taken in account, the cumulated 
loss to the global economic output could reach $100 trillion by 2050.[36]
The Infectious Disease Society of America suggested possible solutions which include frequent 
meetings and workshops for better distribution of the available information about antibiotic 
resistant bacteria in the medical community, and a maximized prevention together with a more 
accurate and selective application of antibiotics. Other suggested actions that could limit the 
diffusion of antibiotic resistance are the improvement of diagnosis, tracking and prescription 
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practices, as well as the optimization of the therapeutic regimens and the adoption of antibiotic 
stewardship programs.[38] Furthermore, pharmaceutical industries and academy have to put 
continuous efforts in research and development programs to be able to offer new classes and 
new compounds effective against bacteria which can be resistant to all the commercial 
antibiotics.[34] Of crucial importance is the strategy to preserve the efficacy of the newly 
discovered drugs by keeping them as reservoir, used therefore to treat only the serious cases and 
kept out of the market. 
The majority of the lead compounds of a certain class of antibiotic are natural products, which 
were discovered from fungi or bacteria, e.g. actinomycetes to gain advantage against their 
antagonists during the evolutionary race. Often these natural products were chemically tailored 
by pharmaceutical companies to achieve better pharmacological properties.[39] Nowadays, over 
ten classes of antibiotics are actually on the market, among them the most used are beta­lactams 
(which include penicillins, cephalosporins and carbapenems), tetracyclines, quinolones, 
sulfonamides, glycopeptides and aminoglycosides. Each class of antibiotic inhibits or competes 
with the natural substrate, such as proteins or DNA/RNA involved in essential pathways of the 
bacterial cell. Beta­lactams are known to inhibit the bacterial cell wall formation, by targeting the 
enzyme responsible for the crosslinking of the peptidoglycan, which leads to instability and 
destruction of the entire bacterial cell wall.[40] Tetracyclines, on the other hand, inhibit the 
synthesis of bacterial proteins by preventing the association of aminoacyl­tRNA within the 
bacterial ribosome,[41] while quinolones inhibit the enzyme DNA gyrase essential for DNA 
replication[42] and sulfonamides inhibited the enzyme involved in the folate synthesis.[43]
Since the decades after the World War II, known as the golden era of antibiotic discoveries, only 
three totally new classes of antibiotics were discovered since the 1970s.[44] The discovery, the 
development and the optimization of new effective antibiotics, which require several years 
before approval and therefore commercialization, led to an innovation gap where no new classes 
of antibiotics were introduced in the market (Figure 1.2). In the years of the innovation gap, most 
of the new drugs introduced were achieved by the synthetic tailoring of the already well known 
scaffolds.[30,45] The discovery of new effective classes of antibiotics in the era of antibiotics 
resistance phenomenon will provide much­needed time to elaborate strategies to reduce the 
incidence of infections and to increase the awareness of the public about this problem. 
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Figure 1.2. Year of market introduction of antibiotics classes with the innovation gap from the sixties to the 
new century.[30]
In March 2017, forty­one new antibiotic drugs, which could be an effective treatment for 
dangerous bacterial infections were in clinical development,[46] however the investments in the 
development of new antibiotics is limited compared to other classes of drugs.[36] Treatments with 
antibiotics are short­term therapies and therefore, from the economic point of view, the 
production of such compounds is not remunerative:[47] pharmaceutical industries prefer to invest 
in the treatment of chronic diseases, which are long­term therapies and therefore request 
continuous supply of according drugs.[48] Governments worldwide try to develop solutions, such 
as allocating public funding for the research on new antibiotics, however, further measures are 
necessary to provide new incentives for investments into antibiotic drugs research. 
Among other antimicrobial candidates, the biopolymer chitosan and its derivatives emerged for 
contemporary antimicrobial research because of their outstanding antimicrobial properties. In 
this thesis, the antibacterial properties of chitosan and some of its functionalized derivatives 
(chitosan thiomers) were investigated, and progress was made in understanding and maximizing 
their efficiency against relevant pathogen strains. Chitosan and chitosan thiomers will be 
introduced in the sections 1.3 and 1.4. 
Chapter 1 ­ Introduction 
7 
1.2 The economic burden of treating cancer 
While bacteria represent an increasing threat for our future, cancer still remains the second most 
urgent medical problem with over 600.000 deaths to be expected only for the year 2017 in the 
USA.[49] Thanks to innovative therapies and early diagnostics, cancer is becoming a more and more 
treatable disease. Due to the high costs, cancer treatments can be hardly affordable even for 
citizens of wealthy countries, such as the USA,[50] not to mention the population of the poor 
countries. Surprisingly, the price of anticancer drugs (and other medications) is significantly higher 
in the USA compared to its neighbors Canada and Mexico, or the European Union. The prices of 
anticancer drugs in the USA from 2000 until now showed a 5 to 10­fold increase that does not 
seem to stop, far ahead of the current inflation. Particularly, some of the anticancer drugs recently 
introduced in the market are priced more than $100.000 per year of treatment, and even when 
having a copayment of 20% the drug still remains hardly affordable also for well insured 
patients.[51] The study of Dusetzina et al. evidenced that high copayment costs often result in 
discontinuous treatments.[52] The high prices of anticancer drugs force many patients (10­20%) to 
not undergo treatment or to compromise significantly the treating plan.[50] The reasons for the 
high costs of anticancer treatments are attributed mainly to companies who are holding the 
monopoly for a certain drug and can thus control the price, which is associated with the 
development and production of the product and with the necessity and the demand dictated by 
the patients. On the other hand, it is convenient that pharmaceutical companies can fix the price 
of anticancer drugs, because in the case prices are controlled by a third party the stimulus for 
innovation will be impaired. However, these motivations seem not to be solid enough and the 
high prices in the USA appear to be unreasonable and without a real justification.  
Fortunately, the situation is different in the other developed countries like Australia, Canada 
Germany and other European Union countries. In fact, consortiums formed of experts in cancer, 
as well as patients’ and pharmaceutical industries’ representatives have established agreements, 
like the Pharmaceutical Benefits Scheme in Australia[53] or the Pharmaceutical Market 
Restructuring Act in Germany, where the available cancer drugs were evaluated based on their 
benefits and reasonable prices were established. In this way drugs are more affordable for the 
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patients and their price are based on their benefits, while still granting a reasonable profit for the 
pharmaceutical industry.[53]
The problem of anticancer prices is especially serious in the low­income countries in Africa and 
Asia. A large part of the population of these countries is generally without a medical insurance 
and does not have the financial means to purchase basic medications, let alone costly anticancer 
drugs, without which the destiny of certain death is inevitable. 
To render anticancer therapies affordable to everyone, more cost efficient anticancer treatments 
are needed. For this purpose, economic and bioactive inorganic cluster compounds, namely 
polyoxometalates (POMs), have been investigated as potential anticancer agents and tested 
against different types of cell lines. POMs could represent a valuable alternative to the available 
expensive anticancer drugs, due to the cost and time efficient preparation processes. To 
investigate the feasibility of POMs as anticancer drugs, the biological properties of some bioactive 
representatives were studied. Moreover, the biological properties of such compounds have been 
investigated either in pristine and in chitosan nanocomposite form. In the present work, 
evidences for the improved selective toxicity against cancer cells of these new materials are 
provided. The presented results pave the way for future in depth in vivo investigations. Some 
general information about POMs and nanoparticles are given in the sections 1.5 and 1.6. 
1.3 Chitosan  
Chitosan is a carbohydrate biopolymer composed of randomly distributed β­(1→4)­linked 
D­glucosamine and N­acetyl­D­glucosamine. This polymer is processed from chitin, so that a lower 
degree of acetylated units leads to its solubility in acidified aqueous solutions. Their different 
degree of deacetylation is responsible for the different solubility of the two polymers, and for the 
higher crystallinity of chitin. The degree of deacetylation (DD) correlates the number of 
deacetylated units to the total number of units: when DD is less than 50% the polymer is becoming 
soluble in acidic solution, and it is referred to as chitosan (Figure 1.3).[54]
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Figure 1.3. Chitin and chitosan structures. 
The protonation of the amine groups of chitosan in acidic conditions allows its solubilization in 
water and renders chitosan the only positively charged natural polymer.[54] Chitin is present in 
many invertebrates and microorganisms where it has a protective role. Essentially isolated from 
the shells of some shellfish, and from particular shrimps, chitin is an abundant side­product of the 
fishing industry.[55] Chitosan is generally produced by industrial deacetylation of chitin: the 
heterogeneous reaction is conducted at high temperatures (120­150 °C) in alkaline media, 
generally sodium hydroxide. However, in this way the obtained material has variable 
physicochemical characteristics, and its production generates a large volume of industrial waste. 
A greener alternative can be the direct extraction from the mycelium of fungi that have chitosan 
in their fungal cell wall. Following this biorefinery approach, chitosan with reproducible 
characteristics, depending on the fermentation conditions, is produced.[56]
1.3.1 Characterization 
To understand and predict the properties of chitosan, the degree of deacetylation and the 
molecular weight should be investigated. Together they are responsible for different properties 
of chitosan such as solubility, metal chelation and antibacterial activity. 
1.3.1.1 Degree of deacetylation 
The degree of deacetylation (DD) of chitosan corresponds to the number of free amine groups 
present: it determinates the pKa of the polymer (generally about 6.3) and therefore the overall 
charge of chitosan at a given pH. Several methods were proposed to determine the DD, such as 
FT­IR[57] and Raman spectroscopy,[58] elemental analysis,[59] or UV­Vis spectroscopy.[60] However 
13C­NMR[61] and 1H­NMR[62,63] spectroscopy are currently the most widely used and reliable 
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The formula (1) does not involve the H1 signal and therefore can be used for room temperature 
measurements, while (2) requires higher temperatures to be able to visualize both the H1 signals. 
The DDs calculated with the different formulas are usually in good agreement. 
1.3.1.2 Molecular weight 
Several methods were proposed to evaluate the MW of chitosan, such as viscosity measurements, 
laser light scattering[64] and HPLC,[65] but the currently most used technique is gel permeation 
chromatography (GPC), also known as size exclusion chromatography. The GPC is usually 
equipped with different types of detector.[66] Generally a viscometer is coupled with a differential 
refractometer and a right angle (90°) light scattering.[67] The eluent is a acetic acid/sodium acetate 
buffer which assures good solubility of chitosan and absence of aggregates.[68] Once the viscosity 
is measured it is possible to determinate the MW using the Mark­Houwink equation:[55]
 (3)
The so­called Mark­Houwink constants (K) and (α) depend on the type of polymer, solvent and 
the temperature used during the viscosity measurement. The constants depend both on the MW 
and the DD of the polymer and consequently, if an accurate MW determination is desired, the 
measurement of the viscosity alone is not enough. Depending on the MW chitosan can be divided 
in oligo­chitosan, low MW chitosan (LMW), medium MW chitosan (MMW) and high MW chitosan 
(HMW). The classification is not universally recognized, but in this thesis the one proposed in a 
recent review is used:[69] chitosan oligomers have a MW of ≤ 16 kDa, LMW­chitosans range from 
> 16 kDa up to 190 kDa, MMW­chitosan > 190 kDa up to 300 kDa and HMW­chitosan covers all 
polymers above 300 kDa.
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1.3.2 Chitosan properties and applications 
Chitosan is a cheap and abundant raw material, which was largely investigated for practical 
applications in different fields like pharmacy, cosmetics, food processing, agriculture and waste 
water treatment.[54] Chitosan is nontoxic, biocompatible, and biodegradable by enzymes present 
in the human body, mainly by lysozyme.[70] All these characteristics are prerequisites for a 
material to be pharmaceutically applicable. Moreover, the possibility to process chitosan in 
different forms like sponge, hydrogels, fibers and films renders it extremely attractive for 
pharmaceutical uses. The most promising applications of chitosan are wound healing and 
regeneration of bones and tissues, thanks to its anti­inflammatories properties, cell growth 
promotion, antimicrobial activity and hemostatic action.[71] Moreover, chitosan and its 
micro/nanospheres, as well as some chitosan derivatives were deeply investigated for drug and 
gene delivery.[72]
Chitosan is also used as additive in cosmetics, for example, for its water retention properties and 
in hair care due to electrostatic reduction.[73] Moreover chitosan is a legal dietary supplement for 
weight loss in many countries, such as Italy, Norway and Japan,[74] although doubts about its 
effectiveness were reported.[75]
As chitosan has well documented antimycotic activities,[69,76] it was also investigated as food 
preserver or material for food packaging.[77]
Chitosan also has enormous potential in agriculture where it was investigated as seed coating, 
resistance elicitor inducing plant defense responses and soil amendment.[78] The ability of 
chitosan to chelate metal ions[79] and other pollutants is currently used in the treatment of 
wastewater.[80]
Many of the applications of chitosan are directly connected to its antimicrobial activity that is 
discussed in detail in the section 2.1.1. 
1.3.3 Functionalization of chitosan 
Chitosan can be easily functionalized on both its alcohol and its amine groups. The 
functionalization is intended to improve chitosan properties, including its solubility, 
mucoadhesivity and antibacterial activity. Chitosan can be selectively functionalized on one 
moiety or on both. This is feasible both protecting the undesired functional group or performing 
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a reaction that targets selectivity the desired moiety.[69] The amine group can undergo a Schiff 
reaction with aldehydes or ketones yielding the corresponding aldimines and ketimines, while 
chitosan hydroxyl groups can be functionalized through esterification or etherification. The 
formation of amide bonds between the amine groups of chitosan and the carboxylic acid of 
different biologically active molecules is a frequently used functionalization pathway and will be 
widely addressed in chapter 2 and 4. 
A wide variety of chitosan derivatives were reported,[81] including quaternized chitosans that are 
functionalized with alkyl chains and showed improved antibacterial properties,[82] the 
phosphorylated chitosans, with improved solubility and used for metal chelation and tissue 
regeneration,[83] the sugar chitosans, that are recognized by the corresponding specific lectins and 
are quite promising for drug targeting,[84] the carboxyalkylated chitosans, that are soluble also at 
physiological or basic pH,[85] the chitosan thiomers (briefly thiomers), functionalized with thiolic 
groups to increase the mucoadhesive properties[86] and many others. 
The present thesis is focused on chitosan as (1) the starting material for the synthesis of thiomers, 
(2) the positively charged organic constituent of polyoxometalate­chitosan nanoparticles and 
(3) the starting material for the carboxymethyl chitosan, which is herein used to prepare further 
polyoxometalate nanoparticles. The positive charge, the biocompatibility and antibacterial 
properties of chitosan are the main reasons why this polymer was chosen. In the following 
paragraphs, both thiomers and polyoxometalates will be introduced from a general point of view. 
1.4 Chitosan thiomers 
Chitosan thiomers are prepared through the reaction between mercapto substituents and the 
amine groups of chitosan. Chitosan thiomers were developed principally in Bernkop-Schnürch’s 
group, as non­invasive drug carriers, due to their excellent mucoadhesive properties.[86]
The first chitosan thiomer to be developed was chitosan substituted with thioglycolic acid 
(chitosan­TGA).[87] Chitosan­TGA showed 10­fold improved mucoadhesion compared to pristine 
chitosan, while exhibiting a good swelling behavior and maintaining its biodegradability. Thiomer 
mucoadhesion is due to the interaction of the sulfhydryl groups with cysteine­rich subdomains of 
mucus glycoproteins of the mucus gel layer. These interactions are based on thiol/disulfide 
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exchange reactions, an oxidation process, or on the formation of disulfide bonds, leading to an 
increased residence time that allows a time dependent release of the carried drug.[86]
Different thiomers were further developed for specific applications as drug carriers.[88] Alkyl chain 
thiols can be attached through amide bonds, like cysteine, N­acetylcysteine and glutathione, or 
amidine bonds, such as thioethylamidine and thiobuthylamidine. Typically, the pKa values of these 
thiols are in the range of 8­10. 
 Aryl thiols such as 6­mercaptonicotinic acid and 4­mercaptobenzoic acid were also used to 
functionalize chitosan due to their lower pKa (5­7), and therefore higher reactivity. Particularly 
6­mercaptonicotinic acid­chitosan showed the highest mucoadhesive properties, measured in 
vitro via the rotating cylinder method and via tensile studies. Thiomers also display good in situ
gelling properties due to the oxidation of the thiols in physiological conditions.[88]
The last trend about thiomers are the S­protected thiomers.[89] They consist of a chitosan­TGA 
whose thiol groups are protected through a sulfur bridge with 6­mercaptonicotinic acid. In this 
way, the thiols are still active in sulfur exchange reactions and are not oxidized before reaching 
the mucosa, thus exhibiting even better mucoadhesion properties. 
 In 2014, the first product containing a chitosan­N­acetylcysteine conjugate for treatment of dry 
eye syndrome was launched on the European market.[90] The antibacterial properties of the 
thiomers, as well as their synthesis and characterization will be further discussed in the second 
and fourth chapter of this thesis. 
Figure 1.5. Schematic structure of a thiomer and S­protected thiomer and schematic interaction of a 
thiomer with a mucus layer.[90]
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1.5 Polyoxometalates 
Polyoxometalates (POMs) are discrete, negatively charged polyoxoclusters of group 5 and 6 of 
transition metals, mainly of molybdenum, tungsten and vanadium and less commonly of tantalum 
and niobium, in their high oxidation states.  
POMs are formed from octahedral subunits of these metal oxides (MO6) which condense together 
to form larger polyanions with a well­defined geometrical structure which is dependent on the 
metal.[91,92]
These compounds are known since 1826 when Berzelius first isolated some molybdenum 
compounds with phosphate and arsenates, while it was Marignac that discovered the first 
heteropolytungstates in 1862.[91] The first structure was assigned by Keggin from powder X­ray 
diffraction data to the heteropolyacid H3PW12O40, that was named Keggin structure in honor of 
its discoverer.[93] Since the 1990s, due to the improvement in characterization techniques, such 
as single­crystal X­ray diffraction, NMR spectroscopy and mass spectrometry, the enormous 
variety of structures and functionalization possibilities of POMs has grown steadily.[92]
POMs can generally be divided into isopolyanions, only formed by a single metal type and oxygen 
atoms, and heteropolyanions which contain an additional heteroatom. Isopolyanions are 
generally less stable than heteropolyanions. By tuning the synthesis conditions, it is possible to 
produce a large library of possible building blocks for each of the transition metals, as summarized 
in Figure 1.6. 
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surrounded by 4 oxygen atoms forming two tetrahedra that are caged by 9 MO6 corner sharing 
units, to form the two lacunary XM9O36 moieties connected by six bridging oxygens. 
Figure 1.7. Most frequent structural motifs of smaller POMs.[97]
The synthesis of POMs is often simple and economical, involving just a few steps and inexpensive 
starting materials such as Na2WO4 for the tungsten­based POMs. Generally, the synthesis starts 
with dissolving the starting material and the addition of a mineral acid. After the acidification MO6
units start to form and polycondensation sets in to produce large POM frameworks.[98] To achieve 
heteropolyanions, heteroatoms are included in the system through addition of specific reagents, 
for example H3PO4 when phosphorous is desired in the structure. The precipitation of the 
products is then triggered by adding the counteranion, such as alkali metal or ammonium cations. 
The different reaction conditions such as temperature, pH, heating method (hydrothermal, 
microwave or reflux), time, the different ratio between the elements, and the addition order, 
often influences the outcome of the synthesis and leads to diverse final products.[92,98] Sometimes 
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suitable for applications in solution, especially for homogeneous catalysis. When combined with 
organic counter ions, POMs are also soluble in some polar organic solvents, like acetonitrile or 
dimethylformamide, thus broadening the scope of possible applications. 
Due to the great variety in structure and possible targeted modifications, the application of POMs 
in various fields[103] such as catalysis,[101,104] molecular magnetism,[105] and medicine[106,107] was 
deeply investigated. The application of POMs in medicine and the possibility to create 
nanocomposites with biopolymers that lead to improved biological properties will be further 
addressed in chapter 3 in more detail. 
1.6 Nanoparticles 
Nanoparticles are particles, which should exhibit at least two of their dimensions in the range 
between > 1 nm and < 100 nm. The lower limit is introduced to avoid single and small groups of 
atoms from being designated as nano­objects, and the upper one is sometimes extended to larger 
sizes, depending on the properties under consideration. 
The peculiar properties of nanoparticles are related to their size limits. Considering the same 
mass, nanoparticles exhibit a higher surface area compared to bulk materials, which generally 
leads to higher activity and accessibility in catalysis. Their size is also responsible for the 
preferential accumulation of nanodrugs in cancer tissue, due to the enhanced permeability and 
retention (EPR) effect.[108]
Different types of nanoparticles were investigated for medical purposes, principally as drug­
delivery systems and as in­vivo imaging agents.[109] The different application possibilities include 
the following particle types: 
­ Polymeric nanoparticles are matrix like colloidal nanoparticles that can be prepared with 
different biodegradable polymers such as polylactide­polyglycolide copolymers, 
polyacrylates, alginate and chitosan. They are generally used as drug carriers.[110]
­ Polymeric micelles are generally composed of amphiphilic or oppositely charged 
copolymers that form a spherical structure, with the drug, protein, or DNA placed in their 
inner core. 
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­ Quantum dots are semiconductor particles, generally consisting of hundred to thousand 
atoms. Their optical and electronical properties strictly depend on their size.[111] Their 
chemical composition can include different elements such as CdS, CdSe, InAs, PbSe. They 
are promising tools for in vivo imaging and diagnostics.[112]
­ Gold nanoparticles are biocompatible, easy to functionalize and to produce with definite 
morphology and size, and they display outstanding bioconjugation properties.[113]
­ Superparamagnetic iron oxide nanoparticles (SPIONs) are nanoparticles of Fe2O3 and 
Fe3O4, generally with 6­15 nm sizes, that display magnetic properties. Upon interaction 
with an external magnetic field, they can be accumulated in a specific target in the human 
body and be used in magnetic resonance imaging or magnetic­field­assisted physical drug 
targeting for cancer therapy.[114] When exposed to an alternate magnetic field, the 
magnetic moment of SPIONs oscillates, producing heat that could be used in the 
hyperthermic treatments of cancer. 
­ Silica and organically modified silica nanoparticles are mesoporous structures, with well­
defined surface properties and tunable pore sizes. They can carry drugs or dyes for 
imaging therapies in their inner core.[115]
­ Liposome based nanoparticles were developed and are currently used in medicine and 
pharmacy as drug carriers,[116] although some studies indicate that they could accumulate 
in the liver and cause hypersensitivity.[117]
­  Engineered viral nanoparticles and artificial viruses have been widely investigated as 
delivery vectors in gene therapy due to their high transfection efficiencies, and also as 
imaging and target delivery systems.[118] Their effective application is complicated due to 
the possibilities of host infections and immunological reactions. 
Some of the described nanoparticles structures are shown in Figure 1.9. 
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are chelated by molecules, mostly proteins, present in the organism forming a kind of corona that 
influences their behavior. It is possible that nanoparticles form aggregates that could be 
sequestered by the reticuloendothelial system and not reach their desired targets. The fate of the 
nanoparticles, between the excretion from the body or their bioaccumulation in certain organs is 
not perfectly clear. Ratios of between 40­50% of elimination through the urinary system were 
measured,[125] but further long­term studies are necessary to exclude the possibilities that 
nanoparticles cause chronic damage to the organism. 
Figure 1.10. Interaction of nanoparticles with cells: possible targets and nanotoxicity mechanisms.[122]
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1.7 Goal and strategy of this work 
The main goal of this work was to explore the biological properties of chitosan thiomers and of 
polyoxometalate­chitosan nanocomposites paving the way to potential future clinical 
applications as easily accessible alternative drug types. Consequently, the present work can be 
divided into three parts. In the first part, chitosan thiomers were synthesized, and their 
antibacterial properties investigated, as well as their cytotoxicity on immortalized cell lines. A 
series of different derivatives was synthesized and carefully characterized to determine their 
structure­activity relationships (SAR). In the second part LMW­chitosan and its derivative 
carboxymethyl chitosan (CMC) were used to prepare nanocomposites with inorganic POMs. Their 
biological activities against bacteria and mammalian cells were screened to evaluate the different 
behavior of the composites compared to their pristine components. Finally, the efficiency of the 
thiomer functionalization was evaluated, focusing on the synthesis of chitosan­TGA, and some 
initial attempts to functionalize chitosan with amino acids and other derivatives are also reported. 
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2. Chitosan thiomers as antibacterial agents 
2.1 Introduction 
Chitosan thiomers were developed as drug carriers as described in the introduction (see section 
1.2) and their pronounced antibacterial properties were deeply investigated in previous studies. 
2­iminothiolane­ (IMI) and acetyl­cysteine­chitosan were investigated against E. coli and 
S. aureus, and IMI­chitosan showed a lower value of minimum inhibitory concentration (MIC) 
compared to chitosan. In the same study the authors proposed that the bactericidal mechanism 
of IMI­chitosan involved the destruction of the bacteria cell membrane.[126] In the same year, the 
antibacterial properties of four different chitosan derivatives, i.e. trimethyl chitosan (TMC), 
carboxymethyl chitosan (CMC) and chitosan­TGA (MMW and LMW) were investigated. From this 
study emerged the versatile antimicrobial agent LMW chitosan­TGA, that is effective after just 30 
min against different microorganisms, namely the gram­positive Streptococcus sobrinus, the 
gram­negative Neisseria subflava and the fungus Candida albicans.[127] To investigate other 
possibilities for the enhancement of the antimicrobial activity along these lines, different thiol 
substitutions and starting material parameters (DD, MW) were investigated in this work. In the 
following chapters a survey on the antibacterial properties of chitosan and derivatives is reported 
to put the present work into perspective. 
2.1.1 Antibacterial properties of chitosan 
The antimicrobial properties of chitosan and its derivatives are known since the second half of 
the last century[128] and the efficiency of chitosan against different bacterial strains such as the 
gram­negative E. coli, Pseudomonas fluorescens, P. aeruginosa, Salmonella typhimurium and
Vibrio parahaemolyticus and the gram­positive Listeria monocytogenes, Bacillus megaterium, 
Enterococcus faecalis, S. aureus, Lactobacillus plantarum, L. brevis, and L. bulgaricus was clearly 
established.[129,130] Although several mechanisms of action were proposed, nowadays there is no 
evidence for an unique and prevailing mechanism of action. The mechanism of action varies 
between gram­positive and gram­negative bacteria, due to the differences between the two 
categories, especially regarding their cell membrane structure, and depends on both the 
microorganism type and on the characteristics of the chitosan (MW and DD).[69] In gram­positive 
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bacteria, chitosan is supposed to target the cell membrane where it binds electrostatically to the 
teichoic acids incorporated in the peptidoglycan layer, thus leading to a destabilization of the 
membrane and to a partial leakage of cell constituents, inducing the death of the 
microorganism.[131] An alternative and possible concurrent mechanism involves the possible 
penetration of LMW chitosan into the cell cytoplasm, where it interacts with the nucleic acids, 
thereby interfering with the normal cellular metabolism.[132] In gram­negative bacteria, chitosan 
is supposed to interact mainly with the negative lipopolysaccharides of the outer membrane[133]
or of the inner membrane.[134] The modifications to the membranes and the consequent leakage 
of cellular material is leading to cellular death. Furthermore, several studies confirmed the 
interference of chitosan oligomers with the nucleic acid synthesis of E. coli, which was also 
detected in the cytoplasm by fluorescent labelling.[132,135]
 Another hypothesis is based on the ability of chitosan to chelate metals at pH higher than 6.5.[136]
Chitosan can sequestrate metals from the outer barrier to destabilize it, as well as from the 
surrounding environment of the bacteria, causing an insufficient uptake of micronutrients and 
eventually bacterial death. However, this hypothesis is not supported by any recent study or 
evidence, and only two studies on the antifungal action of chitosan proposed this mechanism.[137]
The metal chelation mechanism seems to be the one with least reported evidences and most 
controversial discussions in the chitosan community.[138]
Liu et al. considered both gram­negative and gram­positive bacteria and suggested that chitosan 
would deform the cell membrane of both, even if the specific target is depending on the 
microorganism, while afterwards LMW chitosan blocks the nucleic acids, thus interfering with 
protein synthesis.[139] A combination of both pathways, where chitosan attacks in different 
proportions both the membrane and the nucleic acids, depending on chitosan and strain 
characteristics, was proposed as the most evident conclusion.[140] In Figures 2.1 and 2.2 a survey 
of the mechanism of action and of the structure of the cellular wall of gram­positive and ­negative 
bacteria, is reported. 
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Figure 2.1. Mode of action against gram­positive bacteria for chitosan and oligo­chitosan.[69]
Figure 2.2. Mode of action against gram­negative bacteria for chitosan and oligo­chitosan.[69]
Regardless the mechanism of action, the data on the antimicrobial efficiency of chitosan and 
derivatives reported so far are sometimes controversial or substantially different among different 
studies. The antimicrobial properties of chitosan depend strongly on its characteristics (MW and 
DD),[141,142] on the environmental conditions (pH, temperature and ionic strength), as well as the 
microorganism species, which causes the above discrepancies between reported results.[69] Some 
studies thus correlate the mentioned characteristics of chitosan and the resulting antimicrobial 
activity. The impact of MW on the antimicrobial activity appears to be different for gram­negative 
and gram­positive bacteria:[130] LMW chitosan was superior in eliminating gram­negative bacteria, 
Chapter 2 ­ Chitosan thiomers as antibacterial agents 
27 
while higher MWs exerted stronger effects against gram­positive bacteria,[141–143] probably due 
to the differences in cellular membrane structure or due to the involved mechanism. Chitosan 
with a higher DD bears, at the same pH value, a higher positive charge density due to the 
protonation of the amine groups which leads to an enhancement of the antimicrobial activity,[142–
144] more markedly for the gram­negative strains, and to a lower extent for the gram­positive 
strains.[141] This behavior supports the hypothesis of the interaction of the positive charged 
ammonium group and the negatively charged components of the bacteria membranes and 
nucleic acids. Further findings on the enhanced antibacterial activity of quaternary amine 
chitosan derivatives, bearing permanent positive charges, compared to their pristine chitosan 
starting materials support this hypothesis.[82,145] Additionally, the antibacterial properties of 
chitosan are strictly dependent on the environmental pH. Chitosan displayed higher efficiency 
against bacteria at lower pH, because of the higher positive charge density.[130,132] Moreover, 
chitosan at pH > 6.5 is not soluble which reduces its applicability in physiological solution.  
All the above operational parameters should be kept constant or considered when comparing the 
antimicrobial activity of different chitosans and chitosan derivatives.  
2.1.2 Approach in the present work 
The goal of the present project was to investigate the impact that both the substituent and the 
characteristics of the starting material exert on the antibacterial properties of chitosan thiomers. 
Therefore, four different starting materials were chosen for the investigation: three LMW 
chitosans (18, 55 and 90 kDa) and one MMW­chitosan (250 kDa), all of them having a high DD 
(87­94%). To evaluate the effect of chitosan substitution on the antibacterial activity, simple 
commercially available reagents bearing thiol moieties were selected to functionalize the 
chitosans. Five mercapto­carboxylic acids with different structural elements were applied, which 
could be attached to the amine group of chitosan through amide bond formation. Two of them 
bear linear alkyl chains (TGA and mercaptopropionic acid, MPA), one has a methyl group on the 
carbon in position 2 (thiolactic acid, TLA), one is equipped with an additional amine group 
(cysteine, Cys), while the last one displayed an aromatic ring, (mercaptobenzoic acid, MBeA). 
Finally, 2­iminothiolane (IMI) was used to form through ring­opening reaction an amidine bond 
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with a permanent positive charge. The chemical structures of the thiol reagents used for the 
functionalization are summarized in Figure 2.3. 
Figure 2.3. Thiol reagents used to functionalize chitosan. 
To investigate the structure­activity relationships (SAR), a comprehensive analytical 
characterization of all chitosan thiomers is mandatory. Special efforts have been made for the 
determination of DD, MW and degree of substitution (DS). To screen the efficiency of the 
antimicrobial activity of the synthesized chitosan derivatives, a MTT assay, which is normally used 
for viability assessment on mammalian cells, was adapted for bacterial tests. The method was 
first optimized on the gram­negative E. coli and afterwards on the gram­negative P. aeruginosa
and the two gram­positive strains S. sobrinus and Streptococcus mutans. The results evidenced 
the superior efficacy of the derivatives produced with the starting material chitosan 85/20 (MW 
 90 KDa and DD  93%), probably because of their higher DD. Among the derivatives produced 
from chitosan 85/20, chitosan­TGA, ­MPA and ­TLA had most pronounced antibacterial effect. To 
evaluate the effect of the alkyl chain length on the antimicrobial activity, we decided to 
systematically increase the number of carbon atoms of the alkyl chain substituent. Therefore the 
following chitosan thiomers were synthesized and characterized: chitosan­2­methyl­3­
sulfanylpropanoic acid (MSPA), ­mercaptobutyric acid (MBA), ­mercaptohexanoic acid (MHA) and 
­mercaptooctanoic acid (MOA). The reaction scheme as well as the chemical structure of the 
mentioned thiomers are reported in Figure 2.4. 
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Aldrich and abcr GmbH (98%). 3­(4,5­dimethylthiazol­2­yl)­2,5­diphenyltetrazolium bromide 
(MTT) was purchased from Alfa Aesar (Heysham, UK). 
2.2.2 Thiomer synthesis 
2.2.2.1 Amide bond formation: Reaction with mercapto­carboxylic acids 
Published synthesis protocols[87,146] were first applied to synthesize chitosan­TGA. Due to an 
unsatisfactory degree of substitution (DS), the reaction time, the temperature as well as the order 
of the reagents addition were then modified. A detailed paragraph describing all the attempts to 
increase the DS of chitosan­TGA can be found in chapter 4. Chitosan­MBeA synthesis was 
performed as described in a previously published procedure,[147] while halving the concentration 
of EDC due to the low solubility of the highly substituted product. The syntheses of all the other 
thiomers involving the formation of amidine bond were adapted from reported protocols for 
chitosan­TGA and ­MBeA. The synthesis conditions for the most representative derivatives are 
summarized in Table 2.1. 
Table 2.1. Synthesis conditions for the most representative thiomers. 
Substituent
Start. 
Mat. 
Reagent 
(g)
EDC 
(g)
T (°C)
Time 
(h)
TGA­A 85/100 0.5 1 Room T 2
TGA­B 85/20 0.5 1.6 Room T 3 
TLA­A 85/5 0.5 1.2 55 3 
TLA­B 85/20 0.5 1.24 55 3 
MPA­A  85/10 0.5 1.26 Room T 68 
MPA­B 85/5 0.5 1.2 55 3 
MPA­C 85/20 0.6 1.26 40 23 
MSPA 85/20 0.5 1.4 40 21 
MBA 85/20 0.5 1.2 40 24 
MHA 85/20 1 1.24 40 20
MOA 85/20 1 1.4 40 19.5 
MBeA­A 85/10 0.625 1.2 Room T 66 
MBeA­B 85/10 0.65 0.6 Room T 66 
MBeA­C 85/5 0.65 1.2 Room T 66 
L­Cys­A 85/5 0.55 1.3 Room T 3 
L­Cys­B 85/20 0.67 1.1 55 3 
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The typical synthesis procedure for the thiomers is described below in detail. The synthesis was 
performed in inert conditions under nitrogen flow. 500 mg chitosan were dissolved in 4 mL 
1 M HCl for 15 min, and 46 mL water were added to obtain a 1% (w/v) chitosan solution. After 
chitosan was completely dissolved, the functionalizing reagent was added to the solution. EDC 
was added after 10 min while maintaining the temperature of the system for the applied reaction 
time (cf. Table 2.1). The pH of the reaction was adjusted to 5. 300­400 mg reducing agent (TPH) 
were eventually added during the final 30 min. The product was dialyzed in cellulose membrane 
tubing with a molecular cut­off of 12 kDa in the dark at 4 °C against different media, as described 
below, for at least 75 h. The following media were used and changed twice a day: 5 mM HCl (day 
1), 5 mM HCl + 1% (w/v) NaCl (day 2 and day 3), and 1 mM HCl (day 4). The product was then 
freeze dried for 48 h and stored in the dark at ­20 °C until further use. A chitosan sample processed 
without the addition of any reagents was used as a reference in the antimicrobial tests. 
2.2.2.2 Ring­opening reaction: Chitosan­IMI 
The synthesis procedure was adapted from previously reported protocols[126,148] and it was 
modified to achieve a higher DS of chitosan. The reaction was conducted in inert atmosphere and 
in the dark. 500 mg of chitosan reacted with 4 mL of HCl 1 M for 15 min and then 46 mL of water 
were added to achieve a 1% (w/v) chitosan solution. After 10 min, chitosan was well dissolved, 
and the pH was adjusted to 6.5 with a solution of 0.5 M NaOH, followed by the addition of 140 mg 
of DTT and after 10 min of 500 mg of 2­iminothiolane. The pH changed to 5.8 and it was adjusted 
to 6.5 with NaOH 0.5 M. The reaction was continued for 3 h at 55 °C. The solution was dialyzed in 
the dark at 4 °C against different media for 76.5 h. The following media were used and changed 
twice a day: 5 mM HCl (day 1), 5 mM HCl + 1% (w/v) NaCl (day 2 and day 3), and 1 mM HCl (day 4 
and day 5). The product was freeze dried for 48 h and stored in the dark at ­20 °C until further 
use. The scheme of the reaction is reported in Figure 2.5. 
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Figure 2.5. Reaction scheme for the synthesis of chitosan­TBA.
2.2.3 Characterization 
2.2.3.1. NMR spectroscopy 
1H­NMR spectra were recorded at RT or at 75 °C on a 300 or 400 MHz Bruker Avance Spectrometer 
(Billerica, USA) with CP­MAS technology (Cross Polarization­Magic Angle Spinning). The DD of 
chitosan and of the thiomers was calculated according to Hirai.[62] Samples were prepared in D2O 
at a concentration of ≥ 10 mg/mL. 
2D­1H­NMR was recorded for chitosan­IMI, ­TGA and ­MBeA at 75 °C on a 400 MHz Bruker Avance 
Spectrometer (Billerica, USA) with CP­MAS technology. 
Solid­state 13C­NMR was recorded for chitosan­IMI at RT on a 400 MHz Bruker Avance 
Spectrometer (Billerica, USA) with CP­MAS technology. 
2.2.3.2. ζ­potential measurements  
All samples at a concentration of 4 mg/mL in Phosphate Buffer Saline pH 7.3 (PBS) were analyzed 
with a Zetasizer Nano ZS90 (ZEN3690, Malvern Instruments Ltd, Malvern, UK) using Malvern 
disposable folded capillary cells.  
2.2.3.3. Aqueous Gel Permeation Chromatography (GPC) 
MW determination was performed in acetate buffer (0.15 M, pH 4.6­4.7) using a Viscotek GPC 
Max system equipped with a VE 2001 GPC solvent/sample module (Malvern). The separation was 
achieved with one A Guard (Malvern) and two GMPWXL 08025 (Tosoh Bioscience LLC, King of 
Prussia, USA) columns.  
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The detectors used were Viscotek 270 Dual Detector for light scattering and viscosity 
measurements, and Viscotek VE 3580 RI detector or Viscotek UV detector 2600 (Malvern) for 
refractive index and UV measurements, respectively. Methods were calibrated with polyethylene 
oxide and dextran Malvern standards. For each chitosan thiomer weight­average and number­
average MW were determined and the polydispersity index (PDI) calculated. Each sample was 
dissolved in the buffer within a concentration range of 4.5­5.5 mg/mL and filtered through a 
0.22 µm filter before injection.
2.2.3.4. Elemental analysis  
Elemental analysis was performed on a Truespec CHNS­microanalyzer (LECO Corporation, 
St. Joseph, USA). To evaluate the DS of each chitosan thiomers, the molar amount of sulfur was 
correlated with molar nitrogen content, dividing their percentage in weight by their MW. 
2.2.3.5. Thiol group determination  
5,5'­dithiobis­(2­nitrobenzoic acid), DTNB2− or Ellman’s reagent, was used to determine thiol 
group concentrations according to literature protocols.[149] Cysteine (concentration range 
75­350 µM) was used as standard. Absorbance at 405 and 450 nm was measured with a 96­well 
plate reader (Synergy 2 Multi­Mode Reader, BioTek Instruments, Winooski, USA).  
2.2.3.6 FT­IR spectroscopy 
FT­IR spectra were recorded in solid­state sample with a Bruker VORTEX 70 spectrometer. 
2.2.4. Antibacterial activity determination 
2.2.4.1. Bacterial strains and media 
Escherichia coli (ATCC 11775) and Pseudomonas aeruginosa (ATCC 27853) (German Collection of 
Microorganisms and Cell Cultures GmbH DSMZ, Braunschweig, Germany) were subcultivated in 
Luria­Bertani (LB) broth pH 7.0 ± 0.2 (10 g/L tryptone, 5 g/L yeast extract, and 5 g/L sodium 
chloride) at 37 °C under constant rotation (220 rpm). Streptococcus sobrinus (OMZ 176) and 
Streptococcus mutans (OMZ 918) (Institute of Oral Microbiology, University Hospital Zurich, 
Zurich, Switzerland) were subcultivated in Brain Heart Infusion (BHI) broth pH 7.4 ± 0.2 (5 g/L beef 
heart, 12.5 g/L calf brains, 2.5 g/L disodium hydrogen, 2 g/L phosphate, D(+)­glucose, 10 g/L 
peptone, 5 g/L sodium chloride) at 37 °C under constant rotation (220 rpm). All the bacteria were 
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grown in agar plates composed 10% agar in the cultivation medium. Plate Counting Agar (PCA) 
containing 5.0 g/L tryptone, 2.5 g/L yeast extract, 1.0 g/L D(+)‐glucose and 12.0 g/L bacteriological 
agar was used for plate counting experiments. All the media were autoclaved before use.  
2.2.4.2 MTT viability assays 
A log‐phase bacteria suspension containing around 108 colony forming units (CFU)/mL was 
incubated with chitosan thiomers (dissolved in medium/0.9% NaCl (1:1) to reach 2 mg/mL or 
4 mg/mL) at 37 °C and 220 rpm. After 30 or 60 min, aliquots were taken and mixed to a ratio of 
1:10 with 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) (5 mg/mL). After 1 
h at 37 °C, 220 rpm, samples were centrifuged for 10 min at 13300 rpm, the insoluble product 
formazan was dissolved in 1 mL DMSO and the absorbance was measured at 550 and 570 nm 
with a 96‐well plate reader (Synergy 2 Multi‐Mode Reader, BioTek). To ensure sterility of chitosan 
samples, aliquots of chitosan solutions were plated onto LB agar and incubated for 16 h at 37 °C. 
Assays were performed as biological triplicates with technical quadruplicates. 
2.2.4.3. Plate Counting  
A log‐phase bacterial suspension was adjusted to 0.5 McFarland turbidity standard (around 
108 CFU/mL) with medium and incubated for 30 or 60 min with chitosan thiomers (final 
concentrations 20 and 40 µM, in 1:1 medium/0.9% NaCl) at 37 °C and constant rotation. 
P. aeruginosa, S. sobrinus and S. mutans reactions were serial diluted 10‐102‐fold and aliquots 
were plated onto PCA. E. coli were serial diluted 106‐108‐fold and aliquots were plated onto PCA. 
Bacterial cultures that received culture medium instead of chitosan thiomers served as positive 
controls and were serially diluted to 106‐108‐fold. All plates were incubated for 24 h at 37 °C 
before colony counting. Only plates containing between 300 and 10 colonies were used for 
enumeration. Experiments were performed in triplicates. Statistical calculation was performed 
with GraphPad Prism using one‐way ANOVA including Tukey’s test and Mann‐Whitney t‐test 
(p < 0.05). 
2.2.4.4. LIVE/DEAD assays
LIVE/DEAD® BacLight™ Bacterial Viability Kit (Molecular Probes, Oregon, USA) was used according 
to the manufacturer’s protocol. Briefly, bacterial suspensions containing around 108 CFU/mL were 
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incubated with 40 µM chitosan‐MPA (in 0.9% NaCl) for 30 min at 37 °C, washed twice with 
0.9% NaCl (13000 rpm for 2 min) and the dye mixture of the kit was added. After 15 min in the 
dark 10 µL of the sample were immobilized on a glass slide coated with 2% agarose. Imaging was 
performed with a confocal laser scanning microscope (CLSM SP5 Mid UV‐VIS Leica, Wetzlar, 
Germany). Imaris (Bitplane, Zurich, Switzerland) was used as software for image processing. 
2.2.4.5. Cultivation of CAL­33 and HeLa cells  
CAL‐33 and HeLa cell lines (tongue squamous cell carcinoma ACC 447; human cervical cell 
adenocarcinoma CCL‐2) were purchased by DSMZ or ATCC and were cultivated in RPMI‐1640 
supplemented with 1% GlutaMAXTM and 10% heat inactivated FCS (Fetal Calf Serum) and DMEM 
supplemented with 10% heat inactivated FCS, respectively. The cells were subcultivated every 
3‐ 4 d at 80% confluency by trypsinization with 0.05% trypsin‐EDTA (0.05% trypsin and 0.02% 
EDTA) (Thermo Fischer, Waltham, USA) and incubated at 37 °C, 5‐6% CO2 in a humidified 
atmosphere. 
2.2.4.6. MTT cytotoxicity assay 
CAL‐33 or HeLa cells were seeded onto 96‐well plates at a density of 12000 cells per well in 
RPMI‐1640 or DMEM and incubated overnight under standard conditions (37 °C, 5‐6% CO2, 
humidified atmosphere). The cells were treated with different RPMI‐1640/DMEM solutions 
containing chitosan‐MPA at different concentrations (100, 50, 25, 12.5, 6.25, 3.12, 1.56 and 0.78 
µM) and incubated for 24 h in standard conditions. After the cells were washed twice with 
complete medium 10 µL of MTT (5 mg/mL, final concentration 0.5 mg/mL) were added to each 
well and the plated incubated for 4 h. The insoluble metabolic product formazan was solubilized 
with 100 µL of SDS solution 10% (w/v) in 0.01 N HCl and incubated overnight. The optical density 
was recorded at 570 nm using a 96‐well plate reader (Synergy 2 Multi‐Mode Reader, BioTek). For 
each concentration sextets were performed to determine the standard deviation. Results are 
expressed as mean ± SD. Non‐linear regression of the curve was performed with GraphPad 
Prism5. 
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2.3 Results and discussion 
2.3.1 Thiomers synthesis and characterization 
To study the effect of the substitution on the antibacterial activity, chitosan was functionalized 
with aryl, alkyl and amino acids, all of them equipped with a thiol group. The focus was placed on 
the influence of the alkyl chain length of the substituent: starting from thioglycolic acid, the alkyl 
chain length was increased to 2, 3, 4, 6 and 8 carbon atoms, including two branched substituents 
(Figure 2.4). Most of the alkyl thiomers were newly synthesized and they were screened for 
antimicrobial activity with respect to deriving SAR.  
Two different kind of reactions were used, one involves the formation of an amide bond: the 
carboxylic group of the TGA is activated by the carbodiimide EDC forming an O­acyl urea 
derivative as intermediate product, which reacts with chitosan primary amino groups. Even if for 
EDC the best reactivity should be in the pH range from 2.5 to 4.5,[150] the functionalization of 
chitosan was performed at pH 5, because it was reported as the pH leading to the best 
functionalization with thiols.[87] Additional considerations about this reaction or possible 
alternatives will be discussed in the chapter 4 of this thesis. 
The second reaction is an ring­opening reaction involving 2­iminothiolane, proceeding without 
using any catalyst or activator by targeting directly the amine groups of chitosan with the 
introduction of a cationic amidine substructure. 
All produced materials, including the pristine chitosan, were characterized in detail using different 
spectroscopic and analytical techniques to correlate their specific structural properties to the 
observed antibacterial behavior. 
2.3.1.1 Ellman test and degree of substitution 
Special emphasis was placed on the quantification of the amount of sulfur present in the samples 
through Ellman’s reagent assay and elemental analysis. The extent of the functionalization is 
proportional to the amount of sulfur attached to the polymer. Ellman’s reagent[151]
5,5ʹ­dithiobis(2­nitrobenzoic acid) (DTNB2−) is able to react stoichiometrically with the thiolate 
anion (R­S­), producing the yellow compound 5­thio­2­nitrobenzoic acid (TNB2­), which exhibits 
intense light absorption at a wavelength of 410­420 nm and is directly proportional to the sulfur 
content.[152] A scheme of the reaction is shown in Figure 2.6. 
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Table 2.2. Characterization of the synthesized thiomers (n. d. = not detectable). 
Substituent Start. Mat. DD (%) Mw (kDa) ± SD PDI DS (%) SH (µmol/g) ± SD ζ pot. (mV) ± SD
Chitosan 85/20 93.1 92.5 ± 1.1 1.06 n. d. n. d. 29.9 ± 1.0 
TGA­A 85/100 91.1 252.6 ± 0.3 2.17 0.7 91.5 ± 0.5 31.4 ± 0.9 
TGA­B 85/20 93.7 103.2 ± 3.4 1.31 0.5 90.2 ± 0.5 27.6 ± 1.4 
TLA­A 85/5 87.5 25 ± 0.4 1.59 6.2 221.1 ± 2.0 20.6 ± 1.4 
TLA­B 85/20 93.3 124.4 ± 4.4 1.1 3.1 186.7 ± 2.4 29.6 ± 0.9 
MPA­A 85/10 87.1 83.5 ± 2.5 1.12 12.1 164.6 ± 3.9 26.5 ± 0.2 
MPA­B 85/5 88.2 22.5 ± 1.1 1.24 7.3 174.9 ± 3.1 22 ± 0.9 
MPA­C 85/20 93.2 97.6 ± 2.3 1.25 5.1 144.1 ± 2.7 32.5 ± 0.9 
MSPA 85/20 93.1 104.6 ± 8.5 1.22 3.7 206.6 ± 1.7 38 ± 1.0 
MBA 85/20 94.2 87.6 ± 3.9 1.32 1.0 168.3 ± 0.5 32.2 ± 0.8 
MHA 85/20 92.8 96.2 ± 2.4 1.23 4.5 253.7 ± 14 30.3 ± 1.4 
MOA 85/20 93.2 117.8 ± 2.6 1.14 4.3 254.6 ± 24 30.2 ± 0.3 
L­Cys­A 85/5 86 15.6 ± 0.7 1.01 2.8 114 ± 2 13.0 ± 3.7 
L­Cys­B 85/20 88 92.7 ± 9.6 1.19 5.1 152 ± 0.3 23.9 ± 3.5 
IMI­A 85/5 86.9 33.7 ± 10.5 1.44 27.6 304 ± 7 // 
IMI­B 85/10 85.5 109.9 ± 13.7 1.32 25.1 228.3 ± 21 // 
MBeA­A 85/10 81 // // // 524 ± 22 // 
MBeA­B 85/10 86 // // // 224 ± 16 // 
MBeA­C 85/5 84.9 // // 35.0 305 ± 7 // 
The extent of the functionalization, or in other words the DS and concentration of sulfhydryl 
groups, depends strongly on the reactivity of the substituent, on the starting material (lower MW 
seems to be functionalized more easily) and the conditions used in the synthesis (time, 
temperature, pH and inert atmosphere). Chitosan­TGA turned to be the less substituted of the 
synthesized thiomers, with a concentration of sulfhydryl groups of about 90 µmol/g and a DS of 
0.5­0.7%. Multiple attempts to synthesize chitosan­TGA with a higher DS via novel or modified 
literature protocols were performed and more details are discussed in chapter 4. All other 
synthesized thiomers have a DS from 3 to 7% and a concentration of sulfhydryl groups from 150 
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to 250 µmol/g, depending on the reagent and on the reaction conditions. When the sulfhydryl 
groups content of only the thiomers prepared from the starting material 85/20 is considered, 
more uniform DS (from 3 to 5%) were achieved, except for chitosan­MBA which was less 
substituted.
Chitosan­MBeA and ­IMI showed a high DS. The high substitution of the aryl thiomers could be 
explained by the higher reactivity of the carboxylic acid nearby the aromatic ring. If the 
substitution extent is too high, the chitosan­MBeA becomes insoluble. To achieve more soluble 
samples, it was necessary to reduce the amount of EDC. Nevertheless, it was easy to achieve a 
high degree of substitution up to 35% and thiol concentration up to 500 µmol/g. Regarding 
chitosan­IMI, details from two different procedures were incorporated in the synthesis.[126,148] In 
the second study highly substituted material was achieved while using small amounts of starting 
material, while larger amounts of chitosan were used in the first study. Therefore, the second 
reaction was scaled up in this work, still achieving a good DS and high concentration of sulfhydryl 
groups. Taking advantage of the easily achievable substitution, this synthesis is recommended 
when high DS are desired, but chitosan­IMI it is probably not stable (see discussion below). 
2.3.1.2 1H and 13C­NMR spectroscopy 
The successful functionalization of the chitosan backbone can be investigated with NMR 
spectroscopy. When the DS is high enough, the protons of the substituent can be detected by 
1H­NMR spectroscopy. The 1H­NMR spectrum of chitosan­MSPA is reported as representative 
example (Figure 2.8) together with its molecular structure and the assignment of the chemical 
shifts either of the chitosan backbone and either of the substituent. The spectrum displays a well­
defined peak at δ 1.76 ppm related to the methyl group in alpha position. In the case of chitosan­
MSPA the degree of substitution can be evaluated using the integral of the methyl group 
(δ 1.76 ppm), however with this method we obtain a DS of 23.4% that does not agree with the 
one calculated using elemental analysis data. Furthermore, if the DD of chitosan is calculated from 
the integrals of the peaks of the 1H­NMR spectra at 75°C, a lower DD of 88.21% is estimate. 
Anyway, comparing the DD calculated at 75 °C and at room temperature, it was possible to verify 
that the differences between the DD of the single samples are retained at both temperatures. 
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increases from 55 kDa to 110 kDa. Chitosan­MBeA MW was not measured because of solubility 
issues; however, it could be speculated that due to its high DS the MW increases compared to the 
starting material. Both the number­average and the weight­average MW were determinate with 
GPC experiments and the PDI was calculated. PDI values, which indicate the polydispersity of the 
polymer, were ranging from 1.1­1.3 for the thiomers synthesized from chitosan 85/10 and 85/20 
indicating a good uniformity of the polymer chain mass. A polydispersity index higher than 2 was 
calculated for the derivatives synthesized from chitosan 85/100 highlighting the irregular length 
of the polymer chains. This is true in a lesser extent, also for the derivatives of chitosan 85/5. The 
differences in the PDI could either be due to the characteristics of the starting material or be a 
consequence of the reaction conditions. 
2.3.1.4 ζ­potential 
As mentioned above, the pH value exerts a major influence on the antimicrobial efficacy of 
chitosan and its derivatives. Therefore, to exclude this influence, chitosan thiomers were 
dissolved in PBS before to be screened against bacteria. Furthermore, to remain as close as 
possible to the biological conditions, chitosan thiomers were dissolved in PBS to measure their 
ζ­potential and their pH. The pH values after dissolution were around 5.5­6.0 with measured 
ζ­potentials around +30 mV due to the residual protonated ammonium groups. The thiomers 
achieved from 85/5 were the only ones with a low ζ­potential in the range of +10 to +20 mV.  
 2.3.1.5 FT­IR spectroscopy 
FT­IR spectroscopy was not as efficient and insightful as other analytical techniques to 
characterize the different thiomers or to confirm the substitution, except for chitosan­IMI and 
MBeA, which had a high DS. The signal corresponding to the amine vibration at 1587 cm­1 present 
in the starting material (data not shown) disappears in all the alkyl thiomers and in the reference 
chitosan spectra and it is substituted by two signals at 1515 and 1620 cm­1 assigned to the 
protonation of the amine group. The change in the spectra is probably due to the conditions of 
the reaction and dialysis environment (Figure 2.19a) The spectrum of chitosan­IMI displays a shift 
of the bands at 1515 and 1620 cm­1 to 1521 and 1627 cm­1 (Figure 2.19b) because of the formation 
of the amidine bond. Chitosan­MBeA spectrum shows also shifts of the bands at 1515 and 
1620 cm­1 to 1521 and 1627 cm­1, respectively, that could be attributed to the formation of the 
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normal components of the oral flora, which play a fundamental role in the balance of the oral 
plaque and in the formation of dental caries.[158] Control over these strains would thus be 
beneficial for the oral health. 
2.3.2.1 MTT assays screening 
To determine which characteristics of the chitosan starting materials have a major influence on 
the antibacterial behavior and which derivatives show the highest efficacy, an easy and low­cost 
screening assay was set up by adapting and optimizing the well­known MTT­based cytotoxicity 
assay.[159] In contrast to previously described MTT procedures, a protocol that permits a quick 
processing of numerous compounds in many replicates was developed, using a 96­well plates to 
detect the absorbance with a standard plate reader. The modified MTT assay allows the 
quantification of alive bacteria after treatment with chitosans, because of the proportionality 
between the absorbance of the formazan crystals produced by the MTT metabolism and the 
number of viable cells. The linearity of the method was proved under experimental conditions 
(Figure 2.20). 
Figure 2.20. Linearity of the MTT reduction assay. 
The derivatives synthesized from different starting materials were tested at two concentrations 
(2 and 4 mg/mL) and two incubation times (30 and 60 min). The MTT assay results highlighted the 
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remarkable improvements in the antimicrobial effect of chitosan­TGA and ­MPA (and to a lower 
extent of chitosan­TLA) synthesized from chitosan 85/20 in comparison to the others synthesized 
from chitosan 85/5, 85/10, and 85/100 (Figure 2.21). The DD of 85/20 chitosan thiomers 
determined by 1H­NMR spectroscopy was around 93%, thus suggesting that this starting material 
affords chitosan thiomers with higher DD, which is well known to enhance the antimicrobial 
activity. Therefore, chitosan 85/20 was used as starting material for the synthesis of chitosan­
MSPA, ­MBA, ­MHA and ­MOA, which have been tested with MTT assay as well. The MTT assay 
results under the mildest conditions (2 mg/mL and 30 min incubation) showed that the derivatives 
chitosan­TGA and ­MPA exerted the highest antimicrobial activity (Figure 2.21). However, to draw 
more reliable conclusions further antimicrobial investigations with more precise methods were 
required.  
Figure 2.21. MTT results for chitosan thiomers at 2 mg/mL, 30 min of incubation for E. coli, P. aeruginosa, 
S. sobrinus and S. mutans. 
Chitosan­MBeA was tested only against E. coli, while chitosan­IMI was only tested against E. coli
and P. aeruginosa. Despite the high DS of these chitosans, the bacteria were not affected by the 
treatment, showing instead an increase in the population compared to the control (Figure 2.22). 
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This may suggest that a high DS may not be fundamental to maximize the antibacterial activity of 
chitosan thiomers  ̶  on the contrary, it is important to provide enough free amine groups on the 
chitosan backbone to allow the interaction between the positive ammonium groups with the 
bacterial targets. Chitosan­L­Cys did not display any outstanding activity in the MTT assay (Figure 
2.22), however chitosans substituted with amino acids and as well with the D isomer of cysteine 
will be briefly considered in chapter 5.  
As the goal was the identification of a broad spectrum antimicrobial agent among the chitosan 
thiomers, chitosan­IMI, ­L­Cys and ­MBeA with low antimicrobial activity on gram­negative strains 
were not further tested on the gram­positive strains. 
Figure 2.22. MTT results for chitosan­TGA, ­IMI, ­L­Cys and MBeA at 2 mg/mL, 30 min of incubation for E. 
coli and P. aeruginosa. 
2.3.2.2 Plate counting experiments 
Whereas the MTT assay allows for a rapid and convenient screening, the quantitative assessment 
of the antimicrobial efficiency requires more precise methods: plate counting experiments were 
therefore performed. This method is based on counting the bacteria which survive after 
treatment and are able to form a colony onto agar plates after 24 h. Plate counting experiments 
permit through different dilutions of the bacterial suspension to detect a reduction up to 8 log 
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towards the thiomers and chitosan could be useful when the target is only a certain pathogenic 
strain which is growing in biofilms, for example. In fact, several E. coli strains are normally present 
in the flora of the gut,[157] where they are in a symbiotic relationship within the organism: their 
depletion would not bring any health benefits, just causing discomfort eventually.  
On the contrary, the antimicrobial activity of the chitosan thiomers on the other three tested 
strains is outstanding. All the derivatives, as well as reference chitosan, had a strong impact on 
the population of the gram­negative P. aeruginosa and both gram­positive strains S. sobrinus and 
S. mutans (Figure 2.23 a, b and c). It is important to highlight that chitosan alone led to at least a 
4.5­log reduction of colonies for all the three strains, but not to complete eradication of the 
population. In previous reports on P. aeruginosa, however, chitosan inhibition rates were not as 
high as in our study, even at higher concentrations or longer incubation times: chitosans with 30 
and 120 kDa was able to reduce the population of this strain of 94.9%,[160] or of 99.9% when 
chitosans 49 kDa (DD 53%), 285 kDa (DD 76%) and 1080 kDa (DD 98%) were used.[161]
Furthermore, minimal inhibitory concentration (MIC) values of chitosan on S. mutans have been 
reported to range from 1.25 to 5 mg/mL.[162] The variance of these results illustrates how different 
characteristics of the polymer as well as different applied conditions and methodology affect a 
reported chitosan antibacterial activity.  
Whereas the treatment with pristine chitosan already significantly reduced the number of alive 
bacteria, the substitution of chitosan with the thiol­alkyl chains could enhance the antimicrobial 
activity, presumably through hydrophobic interactions between the alkyl chain and the bacterial 
wall proteins.[163] Furthermore, the reaction of the sulfhydryl group with the cysteine of 
membrane proteins could exert a detrimental effect on bacteria.[88] These combined features of 
the chitosan thiomers could lead to a prolonged interaction with the bacterial cell wall, thus 
enhancing the antibacterial activity. All the alkyl thiomer compounds induced at least a 5.6­log 
colony reduction compared to untreated controls. However, a single thiomer which was able to 
eradicate completely all the three strains was not present among the tested derivatives, with the 
efficiency of the single thiomers depending on the selected strain. This is in good agreement with 
previous reports for pristine chitosan[129,130] and for quaternary N­alkyl derivatives.[164] Even 
apparently small differences may have strong implications (such as on the repopulation of 
infected sites) due to the short generation times of most bacteria. Chitosan­TLA, ­TGA, ­MHA and 
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­MSPA worked equally excellent for gram­negative P. aeruginosa leading to a complete 
eradication of the bacteria (8.4­log reduction) and the results were statistically significant 
compared to pristine chitosan (Figure 2.23a). The gram­positive Streptococci displayed an 
inconsistent pattern, with a superiority of chitosan­MOA, chitosan­TLA and chitosan­MBA vs 
S. sobrinus (Figure 2.23b) and of chitosan­MSPA against S. mutans (Figure 2.23c). Advantages of 
chitosan thiomers were clearly visible in S. mutans, where chitosan­MHA, ­MBA, and ­MSPA all 
displayed a statistically significant effect compared to pristine chitosan, and especially chitosan­
MSPA incubations resulted in 8.3­log reduction and the complete eradication of the bacterial 
population (Figure 2.23c). However, even if certain thiomer effects were not statistically 
significant, elimination of all present bacteria in 30 min is key to prevent a recolonization from 
surviving cells. Our findings were supported by the work of Geisberger et al., where chitosan­TGA 
exerted a 5­log CFU reduction on S. sobrinus.[127] In contrast, previous studies on E. coli and 
S. aureus found chitosan­TGA[165] and chitosan­acetylcysteine[126] to be less effective than pristine 
chitosan, probably because of the high substitution degree, which removes the amine groups 
essential for the antibacterial action. Numerical differences in the antimicrobial activity often 
arise from different tested strains, chitosan characteristics and test protocols, which render direct 
comparisons difficult. 
2.3.2.3 LIVE/DEAD Assays 
To verify the actual bactericidal action of chitosan thiomers and exclude the metabolic inhibition 
of the bacteria as a possible pathway, a viability assay was performed.[166] Two fluorescent dyes 
were used to discriminate between alive and dead cells, with SYTO 9 generally labelling all 
bacteria in green, regardless of intact or damaged membranes. In contrast, propidium iodide (PI) 
penetrates only bacteria with damaged membranes, causing a reduction in SYTO 9 fluorescence 
when both dyes are present, and therefore giving the cells a red color. Chitosan­MPA was chosen 
as a representative sample and its effect on bacteria was observed with confocal laser scanning 
microscopy. Untreated cells showed only the incorporation of SYTO 9, whereas PI fluorescence 
was detected after treatment with chitosan­MPA. With killing rates of 99­100% the microscopic 
analyses support the above results from plate counting experiments for P. aeruginosa, S. sobrinus
and S. mutans (Figure 2.24f­2.26f). The case of E. coli is different with both alive and dead cells in 
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Figure 2.28. Nonlinear regression curve fit for the viability MTT assay of chitosan­MPA treatment on CAL­33 
(red) and HeLa (blue) for 24 h (IC50 14.87 µM; R
2 = 0.9999). 
2.4 Conclusion and prospective of chitosan thiomers 
A comprehensive systematic investigation of the antimicrobial efficacy of several thiolated 
chitosans was conducted. Special emphasis was placed on the characterization of chitosan 
thiomers bearing increasing alkyl chain length and their SAR with respect to antimicrobial activity. 
The MTT­based screening evidenced that functionalization, especially when conducted to a high 
extent, does not generally improve the antibacterial activity of pristine chitosan, suggesting that 
a certain amount of free amine groups is necessary to generate antimicrobial effects. In parallel, 
experiments on E. coli, P. aeruginosa, S. sobrinus and S. mutans evidenced the enhanced 
bactericidal effect of moderately substituted chitosan alkyl thiomers compared to pristine 
chitosan. Chitosan was not able to eliminate the bacterial population completely, while for three 
out of four investigated strains, at least one chitosan thiomer per strain was able to do so. The 
ability to eradicate completely a bacterial population is a key feature to be considered for clinical 
applications: even minor amounts of remnant bacteria may turn out to be detrimental over time 
due to their rapid growth which can re­infect the site. Under our experimental conditions E. coli
was scarcely affected by the treatment of alkyl thiomers. This resistance could be useful in the 
treatment of chitosan thiomer­sensitive pathogen bacteria, without harming the commensal 
E. coli population. 
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 The cytotoxicity of chitosan­MPA, as representative chitosan thiomer, was investigated on 
mammalian cells and an IC50 below the concentration applied against bacteria was found. 
However, it is reasonable to assume that the same concentration used for bacteria would not be 
toxic for somatic cells during short exposure times (e.g. 30­60 min).  
The above investigation emphasizes the outstanding antimicrobial properties of N­acyl thiolated 
chitosans and paves the way to the design of new highly efficient, biocompatible and cost­
effective antimicrobial compounds.  
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3. Polyoxometalates and their nanocomposites with 
chitosan as new candidates for biomedical applications 
3.1 Introduction 
Over the past years, polyoxometalates emerged as a promising class of biologically active 
compounds and were investigated against different targets, e.g. bacteria, cancer cells and 
viruses.[106,107,168] However, the clinical use of POMs is not yet feasible, because of their frequently 
undefined stability at physiological conditions and their high unspecific cytotoxicity. A strategy to 
improve the stability and the selectivity of POMs in the physiological environment is based on 
their encapsulation within a biocompatible polymer matrix. The encapsulation would enhance 
POM stability and, at the same time, increase the uptake by specific targets, e.g. cancer cells. In 
this study, well­known biologically active POMs were encapsulated with chitosan and its 
derivative carboxymethyl chitosan (CMC) to investigate their cytotoxicity profile upon 
encapsulation with the biocompatible matrix. In the next sections, a survey on biological activity 
of POMs when used as pristine component or nanocomposite is provided. In particular, the 
changes upon encapsulation in different biomatrices are considered, focusing on chitosan and its 
derivatives. 
3.1.1 POMs in medicine 
The first investigations of POMs on biological targets highlighted their strong antiviral 
properties.[169] The most famous antiviral POM was (NH4)17Na[NaSb9W21O86], a tungsten 
heteropolyanion containing antimony, known as HPA­23 and hereafter abbreviated as {Sb9W21}. 
{Sb9W21} was identified as very promising antiviral compound, active against the murine Leukemia 
and Sarcoma viruses[170] through inhibition of their RNA­dependent DNA polymerase.[171] The 
uptake of {Sb9W21} in C3HBi fibroblasts was investigated and evidences of accumulation after 48 h 
of incubation in the cytoplasm were provided.[172] Furthermore, {Sb9W21} was active against HIV­1 
virus inhibiting its reverse transcriptase in vitro.[173] The in vitro results were very promising and 
therefore {Sb9W21} was chosen to be tested on patients with acquired immune deficiency 
syndrome (AIDS) in the 1980s. In the first screening, {Sb9W21} caused a reduction of the surrogate 
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markers for HIV in four patients.[174] In the first study, after eight weeks of trial, no decisive 
improvements were observed and a third of the patients had to interrupt the treatment because 
of the severe side effects and dose­related haematological abnormalities.[175] In the second trial, 
a persistence or even increase of antigenemia was observed for all the patients together with 
thrombocytopenia for nine of twelve patients, confirming that pristine {Sb9W21} is not a suitable 
anti­HIV drug.[176] Shortly after the first trial, a polarographic study on {Sb9W21} was published 
revealing poor stability of the compound in water solution over the entire pH range and an 
antimony leakage,[177] thus interrupting any further experiments of POMs on humans.  
Polyoxometalates were investigated as anticancer drugs with promising results. The most 
extensively studied anticancer POM was the polyoxomolybdate [TBA]6[Mo7O24]·3H2O 
(abbreviated as {Mo7O24}), where TBA is tert­butyl ammonium, synthesized by Yamase and co­
workers.[178] {Mo7O24} was found to be active against different cancer cell lines, e.g. MX­1 murine 
mammary cancer cell line, Meth A sarcoma and MM46 adenocarcinoma. The proposed 
mechanism is based on the formation of a 1:1 complex between {Mo7O24} and flavin 
mononucleotide (FMN) in mitochondria. Since FMN is the prosthetic group in flavoproteins and 
acts as an electron carrier for the electron transfer (from NADH to coenzyme Q) coupled with ATP 
generation, the formation of the complex could inhibit the synthesis of ATP[179] with a resultant 
antitumor activity. Moreover, {Mo7O24} exhibits higher cytotoxicity in cancer cells compared to 
normal cells because of the selective reduction of {Mo7O24} in the mitochondrial system of the 
cancer cells to the more cytotoxic reduced species (HxMo7O24).[180] Flow cytometry studies 
conducted on human pancreatic cancer cells suggested a dose dependent growth inhibition and 
cellular death pathway occurring by apoptosis.[181] A further study about the anticancer activity 
of a photo reduced product of {Mo7O24}, precisely [Me3NH]6[H2Mo12O28(OH)12(MoO3)4], 
evidenced that apoptosis and autophagy pathways have a role in the death of the cell.[182] Besides
in vitro inhibition experiments on pancreatic cancer cells, tumor expansion rate was studied on 
mice in vivo. The inhibition of tumor growth at doses of 125 mg and 500 mg per body­weight was 
33.5 and 68.3%, respectively, and the mouse body weight was not affected, pointing to good 
tolerability of the compound. In view of the previously reported data {Mo7O24} and its reduced 
species were proposed as promising molecules in the treatment of cancer. 
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Many other POMs were proposed as promising anticancer in original works, such as 
K7Na3[Cu4(H2O)2(PW9034)2]20H2O[183] and [CoW11O39(CpTi)]7− (Cp = η5­C5H5).[184]
Enzymatic inhibition by POMs has been observed in several different enzyme classes.[185]
(NH4)6[P2Mo18O62] was found to be a potent enzymatic inhibitor, with particularly high selectivity 
and an IC50 of 1.5 nM against the protein kinase CK2, a multifunctional kinase which is 
dysregulated in many cancers.[186] The selectivity of POMs in inhibiting certain enzymes was 
suggested to be the responsible feature for the observed biological activity. Furthermore, 
Na10[H2W12O42] and Na33[H7P8W48O184] were selectively inhibiting alkaline phosphatases 
displaying profound anticancer and amoebicidal activity with low cytotoxicity in vitro on normal 
cells (immortalized human corneal epithelial cells).[187]
Polyoxometales were investigated against bacteria alone or in combination with β­lactam 
antibiotics. In particular, highly negative charged POMs like K27[KAs4W40O140] and K18[KSb9W21O86] 
as well as the Keggin­type POM K5[SiVW11O40] showed minimum inhibitory concentration (MIC) 
values of less than 256 µg/mL against 17 different Helicobacter pylori strains,[188] while vanadium 
containing POMs, such as [tert­BuNH3]4[V4O12], were active against Streptococcus 
pneumoniae.[189]
Among other investigated POMs, K7[PTi2W10O40], K4[SiMo12O40] and K6[P2W18O62] were the most 
efficient ones in enhancing the antibacterial activity of β­lactam antibiotics against the methicillin­
resistant S. aureus.[190]
Particularly, K7[PTi2W10O40], from now on abbreviated as {PTi2W10}, was found to be active against 
several enveloped DNA and RNA viruses, inhibiting their replication.[191] Moreover, K6[P2W18O62], 
henceforth abbreviated as {P2W18}, the first representative of the Wells­Dawson structure 
type,[96] displayed a broad spectrum biological activity against bacteria,[192] viruses[193] and cancer 
cells.[194]
Despite the promising results in vitro, the application of POMs in pharmaceutics is still far from 
implemented. A key strategy to render POMs more applicable for medical purposes is based on 
their encapsulation into a biocompatible polymeric matrix, e.g. starch, liposomes or chitosan.  
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3.1.2 POM­biopolymer composites 
The encapsulation of POMs with different biomatrices was investigated with respect to the 
influence on POM cytotoxicity. The nanocomposites of K6H2[CoW11TiO40] and K6[SiW11TiO40], two 
POMs with promising anticancer activity, were prepared using starch microspheres through an 
enveloping method.[195] The encapsulation preserved the structure of the POM and increased its 
stability, while improving the uptake of the POM by cancer cells and reducing the cytotoxicity 
against normal cells. After several hours, a leakage from the microspheres was observed together 
with a partial decomposition of POMs in buffer conditions, highlighting the need for better 
encapsulating agents.  
K6H2[CoW11TiO40] and K6[SiW11TiO40] were encapsulated into liposomes showing results 
comparable to the POM­starch nanocomposites: increased POMs stability and higher cancer 
cellular uptake together with a decreased cytotoxicity, but a partial leakage was again 
detected.[196] More recently [Si2W18Ti6O77]­starch nanoparticles were used for an in vivo study, 
where the POMs were released in a time dependent way, thus prolonging the life span of mice 
bearing cancer and resulting negative in a mutagenicity test.[197]
A valid alternative to starch and liposomes is chitosan, which generates more stable 
nanocomposites with POMs,[198] even if they were generally larger and more polydispersed. 
Chitosan encapsulation is also known to stabilize POMs which undergo structural modifications 
and degradations under certain conditions.[199] It has been observed that the association with 
chitosan could improve the cancer cellular uptake of {PTi2W10}[198] and enhances the anticancer 
activity of [Cs Eu6As6W63O218(H2O)14(OH)4]25­­chitosan nanoparticles compared to the pristine 
POM.[200] In our group, chitosan water soluble derivatives (carboxymethyl chitosan (CMC) and 
trimethyl chitosan), were used to prepare nanoscale POM composites with tunable morphology 
and surface charge, and their cellular uptake and anticancer profiles were studied on HeLa 
cells.[199]
The cytotoxicity and the inhibition of two alkaline phosphatase enzymes of [NaP5W30O110]14­­, 
[V10O28]6­­ and [TeW6O24]6­­chitosan nanoparticles were investigated.[201] Alkaline phosphatase 
enzymes are known to be overexpressed in different cancer types undergoing metastasis. The 
compound [TeW6O24]6­ showed stronger inhibition against tissue non­specific alkaline 
phosphatase when used alone, and against calf intestine alkaline phosphatase when 
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encapsulated with chitosan, respectively. [NaP5W30O110]14­­chitosan nanoparticles displayed the 
highest cytotoxicity (88 ± 10%) at a POM concentration of 10 µM. A follow up study of the same 
group investigated the activity of three different Keggin­type POMs (i.e. [PW12O40]3­, 
[CoW11TiO40]7­, and {PTi2W10},) and corresponding chitosan nanoparticles against HeLa cells.[202]
[CoW11TiO40]­chitosan displayed the highest cytotoxicity against HeLa cells, providing further 
evidence for its anticancer properties, which had been observed elsewhere for its 
nanocomposites with starch and liposomes. Furthermore, [CoW11TiO40]­chitosan displayed low 
cytotoxicity on normal cells (Vero cells), as the prerequisite for as promising anticancer drug. 
Since chitosan is a well­known antimicrobial agent, synergistic effects on its antimicrobial activity 
were evaluated for POM­chitosan nanocomposites. Capsules obtained via the supramolecular 
assembling of polyoxometalates, chitosan and the surfactant cetyltrimethylammonium bromide 
were investigated against E. coli using a growth inhibition assay. Specifically, [H3PMo12O40] and 
(NH4)15{Na[(Mo2O4)6(µ2­SO3)3­(µ2­SO3)]2} were able to reduce the growth of E. coli up to 80%, 
while [H3PW12O40]­capsules and the pristine POMs were not as efficient.[203] The different shape 
and size of the capsules within the POMs containing molybdenum, were reported as possible 
explanation for their higher activity. Fiorani et al. tested [H5PMo10V2O40]­chitosan nanoparticles 
against E. coli, showing a synergic activity that led to the complete eradication of the bacterial 
population at a POM concentration of 0.6 mg/mL.[204] In summary, POM­chitosan nanoparticles 
were proven to be promising antibacterial agents, however, further experiments on different 
bacterial strains are required to draw more general conclusions. 
3.1.3 Approach of the present study 
In this work {Sb9W21}, {Mo7O24} and {P2W18}, were chosen as representative biologically active 
POMs and promising candidates for medical applications for a deeper exploration of their 
biological activity. Special efforts were dedicated to the modification of POM cytotoxicity by the 
encapsulation in chitosan matrices. The association of chitosan and POMs led to the formation of 
nanocomposites, which were characterized in detail with dynamic light scattering (DLS) and 
electron microscopy. Moreover, the stability of POMs in physiological conditions was addressed 
as a key issue for their application. Consequently, the stability of {Sb9W21} and {P2W18} was newly 
investigated before and after the encapsulation processes. 
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The cytotoxicity of the pristine POMs as well as of the nanocomposites was evaluated against 
bacteria (the gram­positive S. sobrinus and the gram­negative E. coli) as well as for different cell 
lines, namely HeLa and MRC­5. HeLa represents an immortal cell line derived from cervical cancer 
cells, while the MRC­5 cell line was derived from normal lung tissue of a 14­week­old male fetus. 
Furthermore, (TBA)4[Mo8O26], K7[PTi2W10O40], K4[SiMo12O40] and (NH4)6[P2Mo18O62], and their 
nanocomposites with chitosan or CMC, were prepared and their cytotoxicity was tested. 
However, they were tested on HeLa as part of a screening plan and therefore no in­depth studies 
were conducted. The focus of our research investigations was mainly on the first three well­
known POMs ({Sb9W21}, {Mo7O24} and {P2W18}), which were more extensively characterized, with 
respect to their cytotoxicity vs. their nanocomposites with chitosan and CMC. Consequently, the 
other investigated POMs will be addressed separately in the next sections. 
3.2 Material and methods 
3.2.1 Materials 
Reagents, including the reference material (NH4)6[Mo7O24], were purchased from Sigma­Aldrich 
(Buchs, Switzerland) and unless otherwise specified used as received. Chitosan 90/5 (DD 90%, 
MW 20 kDa) was purchased from Heppe Medical Chitosan (Halle (Saale), Germany). 
3­(4,5­dimethylthiazol­2­yl)­2,5­diphenyltetrazolium bromide (MTT) was purchased from Alfa 
Aesar (Heysham, UK). 
3.2.2 Instrumental details 
1H­NMR spectra at 10, 25 and 75 °C and 183W­NMR spectra were recorded on a 500 MHz Bruker 
Avance Spectrometer (Billerica, USA) with CP­MAS technology, and 31P­NMR spectra were 
obtained at 25 °C using a 400 MHz Bruker Avance Spectrometer (Billerica, USA) with CP­MAS 
technology. UV­Vis absorption spectroscopy was performed using a Lambda 650 S PerkinElmer 
UV­Visible spectrometer in the range λ=225­800 nm equipped with a Quartz SUPRASIL precision 
cell (10 mm). FT­IR spectra were recorded with a Bruker VORTEX 70 spectrometer. XRD patterns 
were recorded on a STOE STADI P diffractometer in transmission mode (flat sample holders, Ge 
monochromator, and CuKα1 radiation) by using a position­sensitive detector. Suitable crystals for 
single­crystal XRD analysis were selected under polarized light, coated with Paratone­N oil, 
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mounted inside a small fiber loop and placed under nitrogen gas flow at 183 K for protection of 
crystals from air. Crystallographic data collection was performed with an Oxford Xcalibur Ruby 
CCD single­crystal diffractometer (Mo­Kα radiation, λ = 0.71073 Å). Hydrodynamic size and 
ζ­potential were measured with a Zetasizer Nano ZS90 (ZEN3690, Malvern Instruments Ltd, 
Malvern, UK) using polystyrene disposable cuvettes (Sarstedt AG & Co, Germany) and Malvern 
disposable folded capillary cells, respectively. A field emission scanning electron microscope Zeiss 
Supra 50 VP, equipped with secondary, backscattered electron and EDX detectors, a transmission 
electron microscope FEI Tecnai G2 Spirit 120­kV equipped with two digital CCD cameras for image 
acquisition and diffraction analysis and a scanning transmission electron microscopy with 
corresponding detector, as well as Oxford EDX system for elemental analysis were used for the 
acquisition of the images. Elemental analyses were performed at “Mikroanalytisches Labor 
Pascher” (Remagen/Germany). 
 3.2.3 Synthesis and characterization of the starting material 
(NH4)17Na[NaSb9W21O86][170,205] and the pure α­isomer,[206] as well as a mixture of the α­, β­ and 
γ­isomers[207] of K6[P2W18O62] were prepared following the previously reported procedures. 
{Sb9W21} was characterized by single­crystal and powder X­ray diffraction, elemental analysis and 
FT­IR spectroscopy. The stability of {Sb9W21} was investigated by monitoring the pH changes in 
aqueous solution (4 mg/mL) and recording UV­Vis spectra from 225 to 800 nm over 4 d. 
K6[P2W18O62] isomers were characterized by single­crystal and powder X­ray diffraction, 
elemental analysis, FT­IR spectroscopy, and 31P­NMR and 183W­NMR spectroscopy. The stability 
of the {P2W18} isomers was investigated at different pH values (3.5, 7.4 and 12) by recording the 
31P­NMR spectra, monitoring the pH trend (4 mg/mL) and the UV­Vis absorption from 800 to 
225 nm at pH 7.2­7.4 for 4 d. (TBA)4[Mo8O26],[208] H4[SiMo12O40],[95,209] K7[PTi2W10O40][210] and 
(NH4)6[P2Mo18O62][211] were prepared following the previously reported procedures. All POMs 
were characterized by FT­IR spectroscopy and powder X­ray diffraction. (NH4)6[P2Mo18O62] and 
K7[PTi2W10O40] were further characterized by 31P­NMR spectroscopy.  
Carboxymethyl chitosan was synthesized following the procedure proposed by Geisberger et 
al..[212] After the synthesis and lyophilization, CMC was newly dissolved in water and filtered 
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through a 0.22 μm filter to remove the unreacted chitosan. CMC was characterized by 1H­NMR 
and FT­IR spectroscopy. 
3.2.4 Preparation and characterization of the nanoparticles 
POM­chitosan nanoparticles were produced as follow: 1 mL of chitosan solution (8 mg/mL, 
pH 5.5, solubilized in water with HCl) was sonicated at room temperature for 5 min, afterwards 
1 mL of POM solution (4 mg/mL) was added and the mixture was sonicated for further 20 min. 
POM­chitosan nanoparticles were produced at pH 4 using chitosan solubilized with acetic acid. 
POM­CMC nanoparticles were prepared at pH 7.1­7.3 as follows: 1 mL CMC solution (8 mg/mL), 
0.5 mL POM solution (4 mg/mL) and 0.5 mL ultrapure water or PBS buffer were stirred for at least 
30 min before dropwise addition of 0.4 mL CaCl2 (3.5 mg/mL); the mixture was stirred for one 
additional hour before DLS measurements. Chitosan pristine nanoparticles were achieved 
through dropwise addition of sodium tripolyphosphate (TPP) to a stirred solution of chitosan, 
while CMC pristine nanoparticles were produced through addition of CaCl2 to a stirred solution of 
CMC. 
Nanoparticles were further analyzed by SEM and TEM. Prior to SEM characterization, the 
nanoparticles were extensively washed with ultrapure water using a 4 kDa cut­off centrifuge filter 
and resuspended by ultrasonication. For SEM analysis the nanoparticles were deposited on a 
sample holder with a carbon sticky surface and coated with a 4 nm Pt layer. For TEM analysis, the 
nanoparticle solution was deposited for 1 min onto 300 mesh copper grids activated by glow 
discharge. The grids were afterwards incubated 3 times for 15 s with uranyl acetate (1% w/v in 
water). 
Size and ζ­potential of the nanoparticles were measured by DLS, and size as well as pH 
measurements were repeated daily over 3 d to confirm their stability. 
3.2.5 Bacterial strains and media 
Escherichia coli (ATCC 11775, German Collection of Microorganisms and Cell Cultures (DSMZ) 
GmbH, Braunschweig, Germany) was cultivated in Luria­Bertani (LB) broth pH 7.0 ± 0.2 (10 g/L 
tryptone, 5 g/L yeast extract, and 5 g/L sodium chloride) at 37 °C under constant rotation 
(220 rpm). Streptococcus sobrinus (OMZ 176, Institute of Oral Microbiology, University Hospital 
Zurich, Zurich, Switzerland) was cultivated in Brain Heart Infusion (BHI) broth pH 7.4 ± 0.2 (5 g/L 
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beef heart, 12.5 g/L calf brains, 2.5 g/L disodium hydrogen, 2 g/L phosphate, D(+)­glucose, 10 g/L 
peptone,5 g/L sodium chloride) at 37 °C under constant rotation (220 rpm). Plate Counting Agar 
(PCA) containing 5.0 g/L tryptone, 2.5 g/L yeast extract, 1.0 g/L D(+)­glucose and 12.0 g/L 
bacteriological agar was used for plate counting experiments. 
3.2.6 Plate counting experiments 
Bacterial suspensions were adjusted to 0.5 McFarland turbidity standard with medium and 
incubated for 30 min with pristine POMs and POM­chitosan nanoparticles (final concentration 
2 mg/mL) at 37 °C and constant rotation. After preparation of proper dilutions, aliquots were 
plated onto PCA. Bacterial cultures that received medium instead of the tested compounds served 
as positive controls and were serially diluted 106­107­fold and then plated. All plates were 
incubated for 24 h at 37 °C before counting of colonies. Only plates containing between 300 and 
10 colonies were used for enumeration. Experiments were performed in triplicates.  
3.2.7 Cultivation of HeLa and MRC­5 
HeLa cells (human cervical adenocarcinoma cell line CCL­2) and MRC­5 cells (normal lung 
fibroblast cell line CCL­171), purchased by DSMZ, were cultivated in DMEM supplemented with 
10% heat inactivated Fetal Calf Serum (FCS) at 37 °C, 6% CO2 and humidified atmosphere. The 
cells were passaged at 80% confluence by trypsinization with 0.05% trypsin­EDTA (0.05% trypsin 
and 0.02% EDTA) (Thermo Fischer, Waltham, USA).
3.2.8 MTT cytotoxicity assay 
HeLa and MRC­5 cells were seeded onto 96­well plates at a density of 1.2 and 3.0 x 104 cells/well, 
respectively, in DMEM and incubated overnight under standard conditions (37 °C, 6% CO2, 
humidified atmosphere). The medium was replaced by different DMEM solutions containing 
POMs and POM­chitosan nanoparticles at different concentrations. The controls received only 
medium. For POM­chitosan nanoparticles the pH of DMEM was adjusted to 6.5, which was used 
as medium for the controls. The cells were incubated under standard conditions for 24 h. After 
three washing steps with complete medium the cells were allowed to recover for further 24 h. 
After recovery, 10 µL of MTT (5 mg/mL, final concentration 0.5 mg/mL) were added to each well 
and the plate was incubated for 4 h at 37 °C, 6% CO2, in humidified atmosphere in the dark. The 
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insoluble metabolic product formazan was solubilized with 100 µL of a solution of SDS 10% w/v 
in 0.01 N HCl and incubated overnight in standard conditions. The optical density was recorded 
at 570 nm using a 96­well plate reader (Synergy 2 Multi­Mode Reader, BioTek). For each 
concentration sextets were performed to determine the standard deviation. Results are 
expressed as mean ± SD. Statistical analysis of the data was performed with GraphPad Prism 5.
3.2.9 Flow cytometry 
HeLa cells were seeded onto 6­well plates at a density of 18 x 104 cells/well in DMEM and 
incubated overnight under standard conditions (37 °C, 6% CO2, humidified atmosphere). The cells 
were treated for 24 h with 10 µM of P2W18 isomeric mixture diluted in DMEM, while untreated 
cells were used for negative controls and heat­treated cells were used as positive control (2 min, 
80 °C). Cells were washed with PBS and trypsinized. Cells were isolated by centrifugation, washed 
with PBS and resuspended with the Binding Buffer and stained with FITC­Annexin V, propidium 
iodide and Hoechst 33342 (Apoptotic, Necrotic, and Healthy Cells Detection Kit, Genecopoeia 
USA), as suggested by the manufacturer. The stained cells were analyzed with the LSR II Fortessa 
flow cytometer (BD Biosciences) using the 450/50, 530/30 and 610/20 filters for fluorescence 
detection. 
3.3 Results and discussion 
3.3.1 Synthesis and characterization of POMs 
Our research focused on {Sb9W21}, {Mo7O24} and {P2W18}, because among the multitude of well­
known biologically active polyoxometalates, their well­documented specific activity against 
different targets renders them very attractive for future medical applications. Furthermore, other 
biologically interesting POMs, namely (TBA)4[Mo8O26], H4[SiMo12O40], K7[PTi2W10O40] and 
(NH4)6[P2Mo18O62], were synthesized (and their cytotoxicity was basically explored, as discussed 
in section 3.3.5.3). 
 The acclaimed anticancer compound {Mo7O24}[213] was selected as reference. The antitumoral 
activity of {Mo7O24} was previously investigated for its isopropyl ammonium salt, and Yamase et 
al. reported that the countercation does not influence the antitumor activity.[214] Therefore, the 
commercially available (NH4)6[Mo7O24] was selected for the present study. {Sb9W21}[170,205] and 
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Figure 3.5. 183W­NMR spectra of the α­, β­ and γ­isomer mixture of {P2W18}. 
The FT­IR spectra recorded for both the α­isomer and the isomeric mixture of α­, β­, and γ­{P2W18} 
were consistent with the one previously reported,[206,207] and details are discussed in section 
3.3.3. The FT­IR spectra of the α­isomer and the isomeric mixture differed among each other 
exclusively for the peak at 1162 cm­1 which is present only in the isomeric mixture of α­, β­, and 
γ­{P2W18} (Figure 3.6a). The powder­XRD pattern revealed a high crystallinity of the α­isomer 
while the α­, β­ and γ­isomer mixture represented an amorphous material. Surprisingly, the 
comparison between the measured powder­XRD pattern and the one calculated from the 
acquired single­crystal XRD data showed low phase purity of the material (Figure 3.6b), probably 
because of the differences in the water content between the crystals and the presence of some 
residual sodium counterions (see elemental analysis in section 3.3.3). 
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the molecular weight, are important parameters to be considered regarding the size of the 
nanocomposites. The molecular weight of the polymer will change the size of the nanoparticles 
in a directly proportional manner. The degree of deacetylation and of substitution are essential 
parameters in the formation of the nanoparticles, because they mediate the electrostatic 
interactions between the components. In addition to the polymer, the concentration and the 
nature of the POM as well as the reaction conditions (ionic strength and temperature) influence 
the characteristics of the final particles. The quality of nanoparticles produced at different 
temperatures was investigated, and the particles produced at 20 °C had smaller size and PDI 
compared to the one prepared at lower or higher temperatures. POM­chitosan nanoparticles 
were generally smaller and less polydispersed than POM­CMC nanoparticles, whereas the 
nanoparticles of the pristine polymers exhibited the opposite behavior. 
The nanoparticles used in the biological experiments ranged from 90 to 230 nm with a 
polydispersity index of 0.170­0.260, while chitosan nanoparticles produced with TPP were 
typically larger. The characteristics of the most representative nanoparticles tested on different 
biological targets are summarized in Table 3.1. 
The characteristics of the nanoparticles such as size, surface charge and type of polymer are very 
important parameters which influence the metabolism in vivo. According to previous studies, the 
mechanism of the cellular uptake could depend on the nanoparticle size, and nanoparticle around 
150 nm would be preferably internalized via non­phagocytic mechanism.[222] Furthermore, 
nanoparticles of different sizes will be metabolized and accumulated differently,[223] e.g. particles 
below 400 nm could be accumulated in the tumor via the “enhanced permeability and retention” 
(EPR) effect.[224]
The surface charge of the nanoparticles plays a relevant role in the cellular uptake. Chitosan 
nanoparticles have a ζ­potential typically around +20 mV while CMC nanoparticles have a 
ζ­potential of around ­20mV. Negatively charged POM­CMC nanoparticles, when injected directly 
in the blood stream, would accumulate most likely in the tumor cells via EPR effect, while 
positively charge POM­chitosan nanoparticles would be recognized mainly by the mononuclear 
phagocyte system.[225]
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 Table 3.1. Summary of the characteristics summary of some nanoparticles used in this work.  
Label POM Chitosan Size (nm) PDI Tested on 
137 Mo8O26 Chit 105 0.214 HeLa 
158 SiMo12 Chit 166 0.222 HeLa 
174 Sb9W21 Chit 99 0.167 Bacteria 
216 Sb9W21 Chit 171 0.172 Bacteria 
179 P2W18 Chit 188 0.205 Bacteria 
217 P2W18 Chit 178 0.226 Bacteria 
193 / Chit 381 0.155 Bacteria 
151 Sb9W21 Chit 152 0.193 HeLa 
206 Mix­P2W18 Chit 117 0.252 HeLa 
211 Mix­P2W18 Chit 99 0.259 HeLa 
256 / Chit 595 0.203 HeLa 
287 Sb9W21 Chit 134 0.185 HeLa 
290 α­P2W18 Chit 213 0.197 HeLa 
297 Mo7O24 Chit 161 0.178 HeLa 
298 P2Mo18 Chit 178 0.195 HeLa 
300 α­P2W18 Chit 233 0.235 MRC­5 
301 Sb9W21 Chit 182 0.183 MRC­5 
304 α­P2W18 Chit 122 0.21 HeLa 
305 Mo7O24 Chit 187 0.179 MRC­5 
CMC 29 Mo8O26 CMC 225 0.141 HeLa 
CMC 34 Mix­P2W18 CMC 216 0.387 HeLa 
CMC 42 Sb9W21 CMC 96 0.195 HeLa 
CMC 43 PTi2W10 CMC 188 0.361 HeLa 
CMC 48 Mix­P2W18 CMC 168 0.223 HeLa 
CMC 78 α­P2W18 CMC 105 0.381 HeLa 
CMC 79 Sb9W21 CMC 180 0.335 HeLa 
CMC 82 Sb9W21 CMC 173 0.246 MRC­5 
CMC 83 α­P2W18 CMC 148 0.313 MRC­5 
CMC 86 / CMC 313 0.227 MRC­5 
CMC 88 / CMC 276 0.19 HeLa 
CMC 94 Mo7O24 CMC 124 0.277 MRC­5 
CMC 95 Sb9W21 CMC 173 0.415 HeLa 
CMC 98 Mo7O24 CMC 127 0.188 HeLa 
CMC 102 Sb9W21 CMC 109 0.347 HeLa 
The successful encapsulation of the POM inside the polymer was confirmed by FT­IR 
spectroscopy. The FT­IR spectra showed the characteristic IR vibrations of both components 
(Figure 3.15). 
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α­{P2W18} could be easily identified by four characteristic IR bands in the 1100­770 cm−1 range: 
1087, 955, 913 and 729 cm­1 which correspond to the νas (P­Oa), νas (W­Od), νas (W­Ob­W) and 
νas (W­Oc­W) bands, respectively. 
The spectrum of {Sb9W21} displayed the characteristic νas (W­O) bands at 916, 812, and 723 cm­1,
and at 1415 cm­1 a vibration related to NH4+. 
The encapsulation efficiency was determined by UV­Vis spectroscopy. The UV­Vis spectrum of the 
filtrate of the nanoparticles after centrifugation through a 10 kDa centrifuge filter was recorded 
and compared to the spectrum of the pristine POMs. The ratio between the absorbance of the 
filtrate and the absorbance of the pristine POM permits to calculate the encapsulation efficiency. 
Encapsulation efficiencies of 99.7 and of 99.4% were found for α­{P2W18}­ and {Sb9W21}­chitosan 
nanoparticles, respectively. Encapsulation efficiency of about 99.7% was calculated for α­{P2W18}­ 
and {Sb9W21}­CMC nanoparticles. 
The encapsulation in the polymeric matrix improved the stability of {Sb9W21} and did not reduce 
significantly the one of {P2W18}, either as α­isomer or as the mixture of α­, β­ and γ­isomers, as 
shown in Figure 3.16.  
The UV­Vis data suggest that {P2W18} undergoes partial modification upon encapsulation: after 
some time, the nanoparticle suspension probably displays a partial reduction, as indicated by the 
visible light blue coloration of the reduced POM. However, the reversible partial reduction does 
not change the structure of the POM and thus might not be the only factor. The partial alteration 
of {P2W18} takes place within the first h after encapsulation, so that the UV­Vis spectra remain 
stable after the first day.  
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Table 3.2. Elemental analysis of {Sb9W21} and {P2W18} and their nanoparticles with chitosan. 
P 
Mass­%
W 
mass­%
K 
mass­% 
W/P W/K 
Sb 
mass­%
W 
mass­%
W/Sb
α­, β­ and γ­P
2
W
18
 1.39 67.2  48.3  
NP α­, β­, γ­P
2
W
18
 0.30 16.5  55  
α­P
2
W
18
 1.28 68.4 4.99 53.4 13.7    
NP α­P
2
W
18
 0.35 18.8  53.7     
Sb
9
W
21
 14.4 51.5 3.58 
NP Sb
9
W
21
 3.43 12.4 3.61 
Theoretical 1.28 68.23 5.10 53.3 13.4 16.4 57.7 3.57 
The stability of the nanoparticles was investigated by monitoring the pH of the solution as well as 
the size of the particles over 72 h. The stability of {P2W18}­ and {Sb9W21}­chitosan nanoparticles 
was confirmed by the constant pH value of 5.4 over the entire monitoring period, while the pH of 
the CMC nanoparticles remained constant around 7.1 for {P2W18}­CMC and 7.2 for {Sb9W21}­CMC. 
POM­chitosan nanoparticles are stable at pH < 6.5, while at higher pH values aggregation sets in 
due to the deprotonation of the ammonium groups. In contrast, CMC nanoparticles are stable at 
pH above 7 due to the deprotonation of the carboxylic groups. The size of {Sb9W21}­chitosan
nanoparticles remained almost constant over a period of 3 d (from 107 to 114 nm), while for 
{P2W18}­chitosan nanoparticles the size increased during the observation period, from 131 to 
151 nm and from 160 to 188 nm for the isomeric mixture and the α­isomer, respectively, thus 
revealing a partial tendency to agglomerate.  
The tendency to form agglomerates is even more pronounced when POM­CMC are considered: 
the size increased over 3 d from 95 to 113 nm, from 180 to 230 nm and from 187 to 875 nm for 
{Sb9W21}­CMC, α­{P2W18}­CMC and α­, β­ and γ­{P2W18}­CMC nanoparticles, respectively. 
3.3.3.1 Electron microscopy of the nanocomposites 
POM­chitosan and ­CMC nanoparticles were investigated with electron microscopy, namely 
scanning electron microscopy (SEM) and transmission electron microscopy (TEM), to characterize 
their morphology and to confirm the size calculated by DLS. Sample preparation is a key step for 
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Figure 3.24. Results of plate counting experiment for {Sb9W21} and {P2W18} and the respective chitosan­
nanoparticles (NP) on E. coli and S. sobrinus (2 mg/mL, 30 min incubation). 
The antimicrobial activity depended on the strain, the type of POM and the polymer used for the 
encapsulation. The pristine POMs were less effective both on E. coli and S. sobrinus than the 
encapsulated analogues, with almost no reduction of the bacterial population. The encapsulation 
of {Sb9W21} with chitosan exerted higher antimicrobial activity than the two separate components 
on E. coli, with a 2­log reduction clearly due to the joint antimicrobial effect. In contrast, the 
treatment with encapsulated {P2W18} barely resulted in a 1­log reduction, while chitosan alone 
reached at best only a 1­log reduction of colonies. On S. sobrinus {Sb9W21}­chitosan and {P2W18}­
chitosan exerted 4­log and 4.5­log reduction respectively, but pristine chitosan alone achieved on 
S. sobrinus a 6.5 log­reduction, when in solution, and completely eradicated the bacterial 
population when applied as nanoparticles. These data clearly illustrate the low influence that the 
tested POMs have on this bacteria strains and were contextualized with the data previously 
reported as follows. {P2W18} was never tested on E. coli, but was used to treat vancomycin 
resistant S. aureus and in co­treatment with β­lactam antibiotic (oxacillin).[228] Inoue et al. found 
out that {P2W18} enhances the effect of oxacillin at a concentration of 100 µM and 50 µM 
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rendering the strain susceptible. However, no plate counting experiments have been performed 
rendering the comparison of the antimicrobial activity difficult.  
To the best of our knowledge, {Sb9W21} with NH4+ and Na+ as counter anions was never tested on 
E. coli. However, a similar study using K+ as counter anion has been conducted on the gram­
negative H. pylori.[229] In this study, a 6 log­reduction has been achieved treating the bacteria with 
24 µM {Sb9W21} for 12 h. When the bacteria were incubated less than 4 h no significant growth 
reduction appeared. In our work, a higher concentration of POM was used, but with much shorter 
incubation time (30 min). It is not possible to say if the reduction of 1 log is due to the higher 
concentration used or the effect of the counter anion. As far as we know, no studies have been 
conducted on the action of both pristine polyoxometalates on S. sobrinus, so direct comparison 
with our data is not possible. 
In this work, the antimicrobial activity of pristine CMC and of its composites was also investigated, 
but no relevant antibacterial effect was observed, probably due to the functionalization of 
chitosan’s amine groups, which are often referred to as the responsible group for the antibacterial 
properties exerted by chitosan.  
 The plate counting experiments evidenced that none of the pristine POMs as well as the 
composites exhibit a relevant antibacterial action against the two tested strains. However, the 
use of these materials could be of interest for application when is important to have cytotoxic 
action on a tissue, while keeping intact the natural microbial population (e.g. in the small and 
large intestine).  
3.3.5 Cytotoxicity on mammalian cells 
3.3.5.1 Cytotoxicity of {Sb9W21}, {P2W18}, {Mo7O24} and nanocomposites 
{Sb9W21}, α­{P2W18} and {Mo7O24} and respective nanocomposites have been tested on HeLa and 
MRC­5, cervical adenoma and normal lung fibroblast cell lines, respectively, and their viability was 
assessed by MTT assay. The results of {Sb9W21} and α­{P2W18} and their chitosan and CMC 
nanocomposites are reported in Figure 3.25 and in Figure 3.26 for HeLa and MRC­5 cell lines, 
respectively. The survival rates are expressed as percentage where 100% refers to the untreated 
control and the concentration expressed in µM refers to the concentration of the POM 
encapsulated into the nanocomposite. {Sb9W21} and α­{P2W18} chitosan encapsulation was 
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pristine POM, e.g. α­{P2W18} or α­, β­ and γ­{P2W18}, which would then eliminate the cancer cells 
due to their high cytotoxicity. A surprising difference in the cytotoxic effect between the α­isomer 
and the isomeric mixture of α­, β­ and γ­{P2W18} was observed on HeLa cells (Figure 3.30). 
Moreover, the encapsulation of α­, β­ and γ­{P2W18} in both chitosan and CMC reduced the 
cytotoxicity compared to the pristine mixture, whereas for the α­{P2W18} the cytotoxicity 
depended on the polymer.  
Figure 3.30. Survival rates expressed as percentage of HeLa cells after 24 h treatment with α­{P2W18} and 
α­, β­ and γ­{P2W18} and correspondent nanocomposites with chitosan and CMC. 
The IC50 values calculated for α­{P2W18} were 83.42 and 39.05 μM for HeLa and MRC­5 cell lines, 
respectively. Previously reported IC50 values were calculated around 20 µM for MCF­7, SKOV­3 
and HepG2 cancer cell lines, much lower than for HeLa and MRC­5 cell lines.[194] In the same study 
the mechanism of action of α­{P2W18} was investigated, suggesting an influence on the cellular 
redox reactions for the energy production by mitochondria which finally induces cellular death by 
apoptosis. 
α­{P2W18} and α­, β­ and γ­{P2W18} tested on HeLa cells showed a significant difference between 
their IC50 values (83.42 and 16.26 µM), which is most probably due to the change in the position 
of {WO3} triad. In a computational study, the isomer α­1,2­{PTi2W10} exhibited a higher inhibition 
potential against the neuraminidase of a subtypes of the influenza virus A compared to the other 
isomers of {PTi2W10}.[234] The different orientation of the upper {WO3} triad might enhance the 
interaction of the β­ or γ­isomer with some cellular enzymes, causing an acute cytotoxic effect. 
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ICP­MS analysis is appropriate to quantify α­, β­ and γ­{P2W18} uptake by the cells, which 
quantifies the total W content upon acidic digestion of the treated cells. In case of intracellular 
POM localization, another appropriate method for the isolation of the different organelles would 
be necessary to establish the cellular target of the POM. Moreover, cytotoxicity studies should be 
performed also on the pure β­ and γ­ isomers in order to correctly attribute the responsible one 
for bioactivity. 
To better understand the mechanism responsible for the high cytotoxicity of α­, β­ and γ­{P2W18} 
flow cytometry experiments were performed. 
3.3.5.2 Flow cytometry experiments 
To further investigate the death mechanism of HeLa cells upon POM treatment, flow cytometry 
experiments were performed. The isomeric mixture of α­, β­, and γ­{P2W18} was chosen as 
representative compound due to the high cytotoxicity exerted on HeLa cells. After incubation for 
24 h with α­, β­ and γ­{P2W18} the cells were stained with three dyes, which emit in a specific 
wavelength range. Each dye provides information about the condition of the cell as well as about 
death mechanism: Annexin stains apoptotic cells, propidium iodide the necrotic one, whereas 
Hoechst stains all the cells.  
The flow cytometer separates and counts single cells using the diffraction of light to evaluate the 
size and granulometry. Consequently, different cell populations are identified, and the eventual 
presence of unrelated particles and cell clusters can be excluded from the final plot. At the same 
time, the fluorescence signal of the stain is related to a defined cellular population. An untreated 
sample was used as negative control and a heat­treated sample as positive control. In the 
bivariate dot plot of the untreated cells 80% of the population was found to be alive (below left), 
while around 20% of the cells suffered from the trypsinization and were dead (Figure 3.31a). The 
positive control showed a population of 30% of surviving cells, revealing that the used conditions 
(2 min, 80 °C) were too mild to kill the entire cellular population (Figure 3.31b). The sample 
treated with α­, β­ and γ­{P2W18} at a concentration close to the IC50 showed that 99% of the cell 
population was dead (Figure 3.31c). The death pathway evidenced by flow cytometry involves 
both necrosis and apoptosis, even if necrosis seems to be the major mechanism involved. These 
findings on the death mechanism associated with α­, β­ and γ­{P2W18} complement the results 
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Figure 3.32. Cytotoxicity results for HeLa of {P2Mo18}, {P2Mo18}­chitosan nanoparticles, α­{P2W18} and 
α­{P2W18}­chitosan nanoparticles. 
{Mo8O26} showed no cytotoxic effect on HeLa cells at the tested concentrations (Figure 3.33), as 
well as {Mo7O24}. The encapsulation either with chitosan or CMC led to an increased toxicity, as 
in the case of {Mo7O24}. In view of these findings, it can be concluded that the encapsulation of 
hepta­ and octa­molybdates originates more cytotoxic species. The formation of the reduced 
species formed from the interaction of the polymolybdate and the chitosan may explain the 
enhanced toxicity of the chitosan nanocomposites.[181,182]
Figure 3.33. Cytotoxicity results for HeLa of {Mo8O26}, {Mo8O26}­chitosan and {Mo8O26}­CMC. 
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showed lower cytotoxicity against both the tested cell lines, while α­{P2W18} and {Sb9W21} 
exhibited higher toxicity. Surprisingly, the isomeric mixture of α­, β­ and γ­{P2W18} exerted higher 
cytotoxicity compared to the pure α isomer. Further experiments should be performed for in 
depth investigation of the anticancer activity of the isomeric mixture by isolating the pure isomers 
and performing ICP­MS analysis on treated cells for cellular uptake.  
The effect on the cytotoxicity of POMs upon encapsulation was investigated. However, the 
cytotoxic effect was not univocal: the cytotoxicity of the nanocomposite could be either increased 
or reduced, depending on the POM and the matrix used for the encapsulation. Furthermore, the 
tested cell lines play a role in defining the cytotoxicity. The rational design of POM­chitosan and 
POM­CMC nanocomposites is thus not yet feasible without further test experiments due to the 
many parameters involved in the overall cytotoxic effect. Any POM­chitosan and POM­CMC 
nanocomposites should be evaluated individually. Moreover, it is essential for biomedical 
applications to consider the intrinsic toxicity of the encapsulating agent. The cytotoxic effect 
should be attributed to the nanocomposite and the POM therein ­ and not by the encapsulating 
agent itself.  
Two possible ways for selective cancer targeting were proposed and they benefit from the pH 
dependent stability of chitosan and CMC. Further in vitro and in vivo experiments could be 
performed to verify the feasibility of POM­chitosan and POM­CMC nanocomposites as pH 
sensitive drugs.  
The synthesis and characterization of {Sb9W21}, α­{P2W18} and {Mo7O24} and respective 
nanocomposites, as well as their cytotoxicity on HeLa and MRC­5 are reported in a manuscript 
that will be submitted in the next months. 
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3.5 Appendix ­ crystallographic tables 
Table 3.3. Crystallographic data of {Sb9W21}. 
Empirical formula Na O86 Sb9 W21
Formula weight 6355.46 g·mol­1
Temperature 183 K
Radiation wavelength 0.71073 Å
Crystal system hexagonal 
Space group P­62c 
a 17.3851(4) Å 
b 17.3851(4) Å
c 24.0907(16) Å 
α 90° 
β 90° 
γ 120° 
Volume 6305.7(5) Å3
Z 2 
Density calcd 3.347 g·cm­3
Absorption coefficient 21.031 mm­1 (Gaussian) 
Crystal size 0.311 × 0.184 × 0.047 mm3
Independent reflections 4407 [Rint = 0.0660]
Reflections collected 40708 
θ range 2.343­26.364° 
Completeness to θ = 26.32° 0.9981 
F(000) 5424 
Data/restraints/parameters 4407/0/110
R1[I>2σ(I)]a 0.1251 
wR2[I>2σ(I)]b 0.3223 
R1a (all data) 0.1296 
wR2b (all data) 0.3347
Goodness­of­fit on F2 1.245
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Table 3.4. Crystallographic data of α­{P2W18}. 
Empirical formula K6P2W18O62·14H2O
Formula weight 1337.54 g·mol­1
Temperature 183 K 
Radiation wavelength 0.71073 Å 
Crystal system triclinic 
Space group P­1
a 12.8118(5) Å 
b 14.7165(6) Å 
c 19.8231(7) Å 
α 70.062(4) ° 
β 80.413(3) °
γ 64.400(4) ° 
Volume 3167.8(2) Å3
Z 2 
Density calcd 5.055 g·cm­3
Absorption coefficient 33.108 mm­1
Crystal size 0.317 × 0.138 × 0.136 mm3
Independent reflections 21398 [Rint = 0.0586] 
Reflections collected 39528 
θ range 2.186­33.082° 
Completeness to θ = 30.44° 0.999
F(000) 4168 
Data/restraints/parameters 21398/0/939 
R1[I>2σ(I)]a 0.0614 
wR2[I>2σ(I)]b 0.1489
R1a (all data) 0.0749
wR2b (all data) 0.1584 
Goodness­of­fit on F2 1.105 
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4. Chitosan­TGA: synthetic approaches 
The functionalization of chitosan with thioglycolic acid (TGA) turned to be one of the major 
challenges in the present thesis. The reported experimental conditions used to functionalize 
chitosan with TGA are straightforward and do not present any obvious issues. Notwithstanding, 
under these conditions the substitution degree for chitosan­TGA observed by different group 
members was extremely low compared to the results recently reported by Bernkop­Schnürch et 
al. in 2015.[236] Although several attempts were made to reproduce the results published for the 
reported procedures, the expected results were not achieved. This may be due to apparently 
minor, but effectively quite important parameter changes, so that the original synthesis was 
rationally modified to improve the DS. 
The most important changes involve the use of inert reaction conditions, varying amounts of TGA 
and EDC, the activation of TGA by N­hydroxysuccinimide, the activation of TGA separately before 
the reaction, the addition of the reagents in a different order, in addition to the variation of pH, 
temperature and reaction time. The reaction between glucosamine, the monomeric form of 
chitosan, and thioglycolic acid was also investigated, unfortunately without any positive results. 
The DS was calculated from elemental analysis data. The modifications proposed could improve 
the extent of the substitution, however, alternative synthetic routes were explored to further 
enhance the functionalization of chitosan with the thiol moiety ­CH2SH. The Schiff reaction with 
mercaptoacetaldehyde and the reaction with the previously prepared TGA acyl chloride were 
performed to directly functionalize the amine groups of chitosan.  
4.1 Materials and methods 
4.1.1 Materials 
Chitosan with different DD and MW (85/5, 85/10, 85/20, 85/100 and 95/20) was purchased from 
Heppe Medical Chitosan (Halle (Saale), Germany). Thioglycolic acid (97%) was purchased from 
abcr GmbH (Karlsruhe, Germany). TGA with purity > 99% was purchased from Sigma­Aldrich 
(Buchs, Switzerland), as well as all the reagents which are not here reported. 
N­(3­dimethylaminopropyl)­N’­ethylcarbodiimide hydrochloride, known as EDC or EDAC (98%, 
99%, and crystalline) was purchased from Sigma­Aldrich or from abcr GmbH (98%). 
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Mercaptoacetaldehyde as mixture of monomer and dimer (8:2) was purchased from Proactive 
Molecular Research (Florida, USA). 3­(4,5­dimethylthiazol­2­yl)­2,5­diphenyltetrazolium bromide 
(MTT) was purchased from Alfa Aesar (Heysham, UK).  
4.1.2 Reaction with EDC 
To functionalize chitosan with TGA previously published protocols were accurately applied.[87,146]
For clarity, the original procedure is briefly reported: 
4 mL 1 M HCl were added to 500 mg of chitosan, stirred for 15 min, and 46 mL water were added 
to obtain a 1% (w/v) chitosan solution. After chitosan was completely dissolved, EDC was added 
to obtain a final concentration of 50 mM (1.246 g). After dissolution of EDC, 500 mg of TGA were 
added. The pH of the reaction was adjusted to 5. The reaction mixture was incubated for 3 h at 
room temperature under permanent stirring. The product was dialyzed in cellulose membrane 
tubing with a molecular cut off of 12 kDa in the dark at 4 °C against different media, as described 
below, for at least 75 h. The following media were used and changed twice a day: 5 mM HCl 
(day 1), 5 mM HCl + 1% (w/v) NaCl (day 2 and day 3), and 1 mM HCl (day 4). The product was then 
freeze dried for 48 h and stored in the dark at ­20 °C until further use.  
Several conditions were later modified: temperature, time, pH, type of chitosan, supplier and 
purity grade of EDC and TGA, order of addition of the reagents, use of N­hydroxysuccinimide 
(HAS) to activate TGA prior to reaction, as well as the external condition of the reaction set­up 
(dark and/or in inert atmosphere). The addition of undissolved chitosan to the reaction mixture 
was also tested. The conditions of the synthesis of selected chitosan­TGA samples are 
summarized in Table 4.1. The reactions were always performed with 500 mg of pristine chitosan. 
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Table 4.1. Synthesis conditions used for the preparation of selected chitosan­TGA samples. 
Label 
Start. 
Mat. 
TGA 
(g)
EDC (g) HAS (g) T (°C)
Time 
(h)
Comments 
MAC­A­1 85/5 0.5 1.2 // RT 3.5 Water degassed 
MAC­A­14 85/5 0.5 1.8 // RT 3 Inert conditions 
MAC­A­22 85/100 0.5 1  // RT 2 Inert conditions 
MAC­B­8 85/5 0.53 1.1 // 55  5 Inert conditions 
MAC­B­20 85/10 0.5 1.2  // RT 3 Normal with light 
MAC­B­24 85/10 2.65 1.3 // RT 21 Inert, EDC first 
MAC­B­37 95/20 1 1.2 // 40 20 Dark and inert 
MAC­B­38 95/20 1 1.2 // 40 20 Dark and inert 
MAC­C­3 95/20 1 0.4 // RT 3 Inert, TGA first 
MAC­C­4 95/20 0.5 0.4 // RT 3   
MAC­C­5 95/20 0.5 1 // RT 3   
MAC­C­12 85/20 1 0.6 // RT 3   
MAC­C­13 85/20 0.53 1 // RT 3 New TGA, inert  
MAC­C­20 95/20 0.5 0.5 // RT 3 No pH setting, previous activation 
MAC­C­21 95/20 0.5 1 // RT 3 pH 4.5 setting, previous activation 
MAC­C­30 95/20 1 2 // RT 5 
MAC­C­33 95/20 1 1 1.24 RT 3 No pH setting 
MAC­C­35 85/20 1 1 1.24 RT 3 TGA EDC controlled pH 4.2 
MAC­C­41 95/20 1.3 1.2 // RT 5 Solid chitosan, no pH setting 
MAC­C­43 85/20 0.53 1 1.2 RT 3 Solid chitos., pH 4.5 activation TGA
MAC­C­47 95/20 4 1.5 // RT 65 Large volume 
SC­1 85/20 0.5 1.2  // RT 3 Conducted by another researcher 
MAC­D­8 90/20 0.02 0.2 0.12 RT 16 Anh, inert dark prev. activation 
MAC­D­9 90/20 0.5 0.5 0.31 RT 16 Anh, inert dark prev. activation 
MAC­D­13 90/20 0.52 0.6 0.35 RT 21.5 Previous activation 
GG­B­23 85/20 0.5 1.2 // RT 3 Conducted by another researcher 
4.1.3 Schiff Reaction 
Two chitosan­TGA samples were prepared by Schiff reactions with slightly varying procedures. 
MAC­C­31: 4 mL 1 M HCl were added to 500 mg of chitosan and left to stir for 15 min before 
30 mL water were added. To this solution 1 g of mercaptoacetaldehyde dispersed in 20 mL water 
were added dropwise. The reaction mixture was warmed at 65 °C for 3 h, cooled to room 
temperature and dialyzed in cellulose membrane tubing with a molecular cut off of 12 kDa in the 
dark at 4 °C against different media, as described below, for at least 75 h. The following media 
were used and changed twice a day: 5 mM HCl (day 1), 5 mM HCl + 1% (w/v) NaCl (day 2 and 
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day 3), and 1 mM HCl (day 4). The product was then freeze dried for 48 h and stored in the dark 
at ­20 °C until further use. The isolated material was a white polymer­like solid. 
MAC­C­32: 4 mL 1 M HCl were added to 500 mg of chitosan and stirred for 15 min, and 30 mL 
water were added. After chitosan was completely dissolved, it was added dropwise to a 
previously prepared suspension of 2 g of mercaptoacetaldehyde in 20 mL water. The reaction 
mixture was warmed at 80 °C for 3 h, cooled to room temperature and left to stir during the 
weekend. Afterwards, the insoluble unreacted aldehyde was removed by filtration. The filtered 
solution was freeze dried for 48 h and stored in the dark at ­20 °C until further use. The isolated 
material was a white polymer­like solid. 
Figure 4.1. Reaction scheme of chitosan functionalization with mercaptoacetaldehyde. 
4.1.4 Reaction of chitosan with TGA acyl chloride 
Two chitosan­TGA samples were prepared with TGA acyl chloride following slightly varied 
procedures. 
MAC­C­29: The reaction was performed under anhydrous and inert conditions. 12 mL of 
anhydrous dimethylformamide (DMF) were degassed in a round bottom flask with septum for 
10 min prior to the addition of 1.29 g of SOCl2. 1 g of TGA was added dropwise with a syringe. 
After 1 h, a solution of chitosan, prepared by dissolving 500 mg chitosan with 4 mL of HCl (1 M) 
in 20 mL of water, was added dropwise to the reaction mixture. After complete addition of 
chitosan, the reaction mixture was left at room temperature. After 3 h, 50 mL of water were 
added, and the pH of the solution was set to 9 to precipitate chitosan. The precipitate was washed 
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with deionized water and dried in air for 4 d. 5 mL of 1 M HCl were added to the dry product, left 
to react for 1 h and then 50 mL deionized water were added to solubilize the product. The 
dissolved product was dialyzed according to the protocol reported in section 4.1.3 and then 
lyophilized and stored in the dark at ­20 °C until further use. A brownish fluffy solid was obtained. 
MAC­C­36: The reaction was performed under anhydrous and inert conditions. 12 mL of 
anhydrous DMF and 1 g of TGA were degassed in a round bottom flask with nitrogen flow. After 
10 min, 1.29 g of SOCl2 were added dropwise to the reaction mixture. After 1 h a chitosan solution 
(300 mg of chitosan in 10 mL of acetic acid 1% v/v) was added dropwise. Precipitate formation 
was observed. After 1 h of reaction at RT the reaction mixture was dialyzed as described in section 
4.1.3. After dialysis, a precipitate was removed by filtration and a brownish fluffy solid was 
isolated. 
Figure 4.2. Reaction scheme for the preparation of TGA acyl chloride and its reaction with chitosan. 
4.1.5 Characterization of the products 
The products were characterized by 1H­NMR spectroscopy, elemental analysis and Ellman test as 
described in section 2.2.3. Antimicrobial activity was tested with MTT (for bacteria cultivation and 
MTT assay conditions cf. section 2.2.4).  
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4.2 Results and discussion 
In this section, the outcomes of the functionalization of chitosan with TGA are reported and 
correlated to the conditions used for the synthesis. Elemental analysis was performed to evaluate 
the DS and to quantify the total amount of sulfur bound to chitosan. TGA contains one sulfur atom 
and chitosan one nitrogen atom per sugar unit. Therefore, the molar ratio S/N can be calculated 
by dividing the percentage of each element by the molecular weight, which then affords the DS. 
The Ellman test was performed on representative derivatives to quantify and correlate the 
number of unreacted thiols to the conditions of the synthesis. 
4.2.1 Considerations about the EDC reaction 
The conditions which have major impact in the functionalization of chitosan­TGA were previously 
analyzed by Bernkop­Schnürch et al. during their first synthesis of such thiomers. In their first 
publication on chitosan­TGA, the impact of the pH and the ratio between chitosan and TGA on 
the concentration of sulfhydryl groups was investigated.[87] The highest concentration of 
sulfhydryl groups was achieved at pH 5, using a mass ratio of chitosan to TGA 1 : 1 (Figure 4.3). 
Figure 4.3. Concentration of thiol groups for chitosan­TGA correlated to the synthesis conditions.[87]
The functionalization of chitosan­TGA was evaluated by the Ellman test and a concentration of 
sulfhydryl groups of 40 μmol/g was calculated. All measured concentrations are very low and 
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would usually fall within the non­linear absorption range of the calibration curve typically 
recorded in our laboratory. Moreover, the authors did not report elemental analysis data in any 
of their publications. The conditions reported by Bernkop­Schnürch were reproduced by three 
different group members altogether: despite the operator change, the DS calculated by elemental 
analysis was always 1.3­1.5% (MAC­B­20, SC­1, GG­B­23) and the thiol concentrations were 
around 140 μmol/g. Although the thiol concentration was higher compared to the original paper, 
higher concentrations still appear to be possible to achieve, because in a more recent publication 
by Bernkop­Schnürch at al. the successful substitution of chitosan with higher TGA amounts was 
reported.[89] Although higher thiols concentrations (340 μmol/g) were achieved, no changes in 
the synthesis procedure were reported and the author always referred to the original synthesis 
of 2001.[87] However, higher amounts of TGA and EDC were used according to the experimental 
part[89] and the reaction procedure was slightly modified. For example, in a publication of 2015, 
TGA was previously activated by EDC and then dropwise added to the chitosan solution.[236] This 
rendered the reproduction of such procedures somewhat difficult. The pre­activation of TGA with 
and without the addition of N­hydroxysuccinimide (HAS) was also done in this work. HAS is usually 
adopted in peptide synthesis for the activation of carboxylic acids.[237] The reaction did not work 
as expected (MAC­C­20, ­C­21 and ­C­35) with achieved DS ranging from 0.1 to 1.5%.  
It has been reported that the DS increases proportionally with the amount of TGA used in the 
reaction.[89,153,238] Lee at al. observed that a higher amount of TGA compared to the one used by 
Bernkop­Schnürch’s group and a reaction time of 5 h led to a concentration of 360 µmol of thiol 
groups per gram of chitosan.[153] Cathell at al. prepared chitosan­TGA using a large excess of TGA 
(5 g) and a larger reaction volume (400 mL) obtaining a DS of 116% calculated from elemental 
analysis data.[238] A DS higher than 100 could signify that the hydroxy groups of chitosan were also 
functionalized or that the dialysis procedure was not successful. The synthesis conditions 
proposed by Lee and Cathell were reproduced as well, and DS values of 0.4 and 1.5% (MAC­C­30 
and ­C­47) were achieved.  
In light of the above reproducibility issues, other less obvious parameters in the synthesis set­up 
which could influence the substitution degree were investigated. Both the absence of light and of 
oxygen in the reaction environment influenced the reaction outcome. However, other 
parameters such as the amount of TGA, time and temperature of the reaction had to be modified 
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to achieve higher DS. The chitosan­TGA samples with highest DS values were prepared under inert 
conditions, such as MAC­B­8 with a maximum DS of 3.54% and 140 μmol/g thiol concentration. 
The sample was prepared under nitrogen flow at 55 °C for 5 h using EDC of crystalline grade. The 
second highest DS of 2.52% (MAC­B­24) with a thiol concentration of 100 μmol/g was prepared 
using a higher amount of TGA (2.65 g) and a reaction time of 21 h. The low amount of free sulfur 
calculated from Ellman test results for both thiomers is probably due to the longer reaction times 
(and higher temperature) applied. In Table 4.2 the DS values of the most representative 
synthesized chitosan­TGA are summarized. 
Table 4.2. DS of the most representative chitosan­TGA samples prepared with EDC activated reactions 
(bold: maximum degree of substitution). 
Label Start. Mat. DS (%)
MAC­A­1 85/5 2.12 
MAC­A­14 85/5 2.36 
MAC­A­22 85/100 0.57 
MAC­B­8 85/5 3.54 
MAC­B­20 85/10 1.53 
MAC­B­24 85/10 2.52 
MAC­B­37 95/20 0.60 
MAC­B­38 95/20 0.97 
MAC­C­3 95/20 1.51 
MAC­C­4 95/20 0.79 
MAC­C­5 95/20 1.30 
MAC­C­12 85/20 1.38 
MAC­C­13 85/20 1.32 
MAC­C­20 95/20 0.30 
MAC­C­21 95/20 0.07 
MAC­C­30 95/20 0.43 
MAC­C­33 95/20 0.53 
MAC­C­35 85/20 1.04 
MAC­C­41 95/20 0.90 
MAC­C­43 85/20 0.76 
MAC­C­47 95/20 1.47 
SC­1 85/20 1.42 
MAC­D­8 90/20 1.06 
MAC­D­9 90/20 0.84 
MAC­D­13 90/20 1.48 
GG­B­23 85/20 1.28 
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The functionalization of chitosan with TGA was successful to a certain extent. To investigate the 
effect of the substitution on the antimicrobial activity, higher DS were desired. Consequently, 
other synthetic approaches were investigated, i.e. the formation of a Schiff base and the reaction 
of chitosan with TGA acyl chloride (TGA­AC). 
4.2.2 Other functionalization strategies 
Several examples of chitosan functionalization with aldehydes were reported.[239] In fact, the 
amine groups of chitosan can form Schiff bases with aldehydes. The reaction between chitosan 
and mercaptoacetaldehyde (MAA) was performed and two products with DS of respectively 2.6 
and 6.1% and thiol concentrations of 110 and 114 μmol/g, respectively, were achieved. The higher 
temperature and longer reaction time led to higher substitution degrees. The low amount of free 
sulfur is probably due to the presence of dimers in the starting material or to their possible 
formation under the conditions of reaction. The low solubility of MAA in water posed a reactivity 
issue. An alternative way to directly functionalize chitosan with TGA involves the formation of a 
TGA­AC intermediate, followed by its reaction with the amine groups of chitosan. The formation 
of the TGA­AC intermediate was performed with thionyl chloride in DMF which can as well 
catalyze the reaction under inert conditions.[240] The addition of the previously dissolved chitosan 
eliminates the excess of thionyl chloride, meanwhile TGA­AC also reacts with water to form TGA. 
The reaction is competitive with respect to the amine group of chitosan and water, which is 
present in excess. Nevertheless, DS values of 4.1 and 30.8 were achieved. 
Table 4.3. Characteristics of chitosan derivatives synthesized via MAA and TGA­AC. 
Label 
Start. 
Mat. 
Reagent  SH (µmol/g) DS 
MAC­C­29 95/20 TGA­AC nd 4.1 
MAC­C­36 95/20 TGA­AC nd 30.8 
MAC­C­31 95/20 MAA 110 2.6 
MAC­C­32 95/20 MAA 114 6.1 
For both chitosan­TGA samples synthesized via MAA and TGA­AC, the DS achieved could also be 
related to the residual starting material, which could not be removed by dialysis or filtration, 
because of the poor solubility in water. Moreover, the brownish color of the products isolated 
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from the acyl chloride synthesis could suggest the presence of some impurities. To verify the 
structure of the final products 1H­NMR spectroscopy was performed. The presence of impurities 
was observed in the spectrum of sample MAC­C­36 with the highest degree of substitution, while 
in the spectra of MAC­C­29, ­C­31 and ­C­32 only the signals related to chitosan were present, 
while no signals related to impurities were observed. In view of these data, the Schiff base route 
can be considered as alternative to the reaction with EDC. To obtain higher DS values, the 
complete solubilization of both aldehyde and chitosan would be necessary, so that other solvent 
mixtures should be investigated. The purification process should also be improved to ensure the 
complete removal of the starting reagents. 
4.3 MTT test results 
Efforts to improve the DS of chitosan­TGA were made in the first place to investigate the effect 
on the antimicrobial activity compared to pristine chitosan or to less substituted chitosan­TGA. 
To this end, E. coli was preferred over the other strains testes in this work due to its high 
resistance towards chitosan. The MTT tests were performed under the same conditions as 
described in chapter 2, applying 2 and 4 mg/mL of compound and 30 and 60 min incubation time. 
Figure 4.4 shows the results of the MTT test at 2 mg/mL, 30 min of incubation on E. coli for 
selected chitosan­TGA samples. 
Chapter 4 ­ Chitosan­TGA synthesis approaches 
117 
Figure 4.4. MTT results for different chitosan­TGA samples (2 mg/mL, 30 min of incubation vs. E. coli). 
Focusing on the DS, the antimicrobial activity decreased with increasing DS (MAC­A­22, ­B­
24, ­B­8). Surprisingly, the Schiff base MAC­C­31 with a DS of 2.63% was the most active 
compound of the series. The observed MAC­C­31 efficacy could also be due to the different 
starting material with a higher DD. The two samples with highest substitution degrees which were 
prepared from the same starting material (MAC­C­29, ­C­32) display rather poor antimicrobial 
activity. MAC­C­29 showed lower antimicrobial activity, probably because of the low 
concentration of thiol groups. As mentioned in chapter 2, a high DS is not a necessary criterion 
for high antimicrobial activity: against certain strains, DS of 2­3% or lower (MAC­A­22, MAC­B­24 
and MAC­C­31) are enough to obtain significant antimicrobial activity. Moreover, other 
characteristics, such as MW and DD have to be considered. A valuable tool to correlate the 
characteristics of chitosan thiomers (DD, MW and DS) and the antimicrobial properties could be 
chemometrics.  
The preliminary biological data presented in this chapter are not yet conclusive. A broader 
selection of tested bacteria and more reliable and quantitative methods, such as plate counting, 
should be used. 
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4.4 Conclusions 
Highly substituted TGA samples with sufficient quality for antimicrobial tests could not be 
obtained from literature protocols. After modifying the synthetic conditions, a maximum DS of 
3.54% was achieved via EDC activated synthesis. Alternative reaction pathways led to higher DS 
values, but most probably some traces of the reagents were present after dialysis. The MTT 
experiments confirmed that a higher DS of the thiomers is not improving the antibacterial 
properties, while a DS of 2­3% led to maximum antibacterial activity. 
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5. Further chitosan functionalization 
In this chapter, the synthesis and the characterization of chitosan functionalized with amino acids, 
salicylic aldehyde and isopropylsulfonyl chloride are reported, alongside with the antibacterial 
screening of chitosan functionalized with amino­acids against E. coli and P. aeruginosa. 
5.1 Substitution of chitosan with different amino acids 
Chitosan­L­Cysteine (L­Cys) was synthesized and screened together with other thiomers for 
antibacterial activity. Chitosan­L­Cys exhibited a very low antibacterial activity. Chitosan­L­Cys 
prepared with chitosan 85/20 (max. DD) at 4 mg/mL even enhanced the growth of the bacterial 
population over 1 h. Surprisingly, chitosan substituted with D­Cysteine (D­Cys) showed higher 
antimicrobial efficacy compared to the L­isomer. In view of these results, the antimicrobial activity 
of chitosan substituted with different L­ and D­amino acids (AAs) was investigated. The original 
idea was to functionalize chitosan both with L and D isomers of cysteine, alanine, serine and 
lysine. In the end, only chitosan derivatives with L­ and D­cysteine/alanine were characterized 
and tested for antimicrobial activity. 
Chitosan was functionalized through EDC­activated amide bond formation, according to similar 
procedures used to prepare chitosan thiomers.[87] Furthermore, tert­butyloxycarbonyl (BOC) was 
considered as a protective group and serine­BOC was used to functionalize chitosan. The 1H­NMR 
spectrum of a synthesized chitosan­serine displayed the signal assigned to BOC, i.e. the de­
protection of the amine groups was not complete, probably because of the use of HCl instead of 
trifluoracetic acid. The signals related to the functionalization with serine were also present. Due 
to the de­protection problems encountered, it was decided to functionalize chitosan via the direct 
reaction with the amino acids, avoiding the BOC protection of the amine group. L­Ala­chitosan 
was synthesized using the protected L­Ala­BOC purchased directly from Sigma­Aldrich. 
The synthesis conditions used to functionalize chitosan with AAs were similar to those used for 
the synthesis of thiomers, aiming for high DS. All the products were purified by dialysis and freeze 
dried as described in section 4.1.2. The chitosan­AAs prepared from 0.5 g chitosan 85/20 were 
prepared as reported in Table 5.1.  
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Table 5.1. Synthesis conditions applied for the preparation of chitosan­AAs. 
Substituent Label 
Start. 
Mat. 
Reagent 
(g)
EDC 
(g)
T (°C)
Time 
(h)
L­Cys MAC­B­2 85/20 0.67 1.1 55 3 
D­Cys MAC­B­25 85/20 1.380 1.2 40 24 
D­Cys MAC­B­26 85/20 0.69 1.2 RT 3 
L­Ala MAC­C­28 85/20 1.012 0.5 RT 23 
D­Ala MAC­C­27 85/20 1.06 0.5 RT 21 
Chitosan­L­Cys and ­D­Cys were characterized by 1H­NMR spectroscopy, Ellman test and 
elemental analysis. The 1H­NMR spectrum of chitosan­L­Cys (MAC­B­2) and of chitosan­D­Cys 
(MAC­B­25) displayed no signals related to the substitution. The 1H­NMR spectrum of chitosan­
D­Cys (MAC­B­26) showed a peak at δ 2.72 related to the substitution with cysteine (Figure 5.1). 
Chitosan­D­Cys syntheses differ through the use of EDC without HCl. The presence in the 1H­NMR 
spectrum of the signal at δ 2.72 ppm could be explained by the superior catalytic performance 
the HCl­free EDC. The Ellman test of chitosan­L­Cys and ­D­Cys evidenced a low concentration of 
sulfhydryl groups (70 µmol/g). The DS calculated from elemental analysis data were 5% for 
chitosan­L­Cys (MAC­B­2) and lower for chitosan­D­Cys (1.3% and 1%, respectively for MAC­B­25 
and ­B­26). 
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Figure 5.3. MTT results for different chitosan­AAs at 4 mg/mL, 60 min of incubation for E. coli and P. 
aeruginosa (nd = not determined). 
This behavior could be attributed to the impairment of enzymatic metabolism through the 
D­amino acids. To further investigate the effect of the stereoisomerism of the AAs on the 
antibacterial activity of chitosan­AAs, PCA experiments would be necessary, as well as the 
evaluation of antibacterial activity of chitosan substituted with other types of AAs, both as D and 
L isomers. 
5.2 Other functionalized chitosans 
Chitosan was functionalized with salicylic aldehyde and with isopropylsulfonyl chloride to 
investigate the antimicrobial properties of these new compounds. 
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5.2.1 Chitosan­salicylic aldehyde 
Figure 5.4. Reaction scheme of chitosan functionalization with salicylic aldehyde. 
The direct reaction between chitosan and salicylic aldehyde led to the formation of a Schiff base. 
Chitosan was solubilized in 40 mL acetic acid (1% v/v) over 48 h prior to addition of the aldehyde. 
After 6.5 h at RT, the reaction mixture was extracted with ethanol. The yellow organic phase was 
concentrated at the rotary evaporator to give a yellow Plexiglas like polymer. The aqueous phase 
was dialyzed and freeze dried as reported in section 4.1.2. The FT­IR spectrum of the yellow solid 
showed the presence of the bands related to chitosan and to the aldehyde. The yellow solid was 
not soluble in water and therefore its antibacterial activity was not investigated. The 1H­NMR 
spectrum of the freeze dried solid displayed the only signals of chitosan and none of the 
substituent. 
5.2.2 Chitosan­2­hydrosulfonylpropane 
The reaction was performed directly between chitosan, which was previously dissolved in 30 mL 
acetic acid (1% v/v) and isopropylsulfonyl chloride at RT for 6 h. The reaction mixture was filtered 
to separate the poorly soluble isopropylsulfonyl chloride, and the filtrate was dialyzed and freeze 
dried as reported in section 4.1.2. The 1H­NMR spectrum confirmed the substitution, showing a 
douplet at δ 1.21 ppm corresponding to the methyl groups of the substituent (Figure 5.6). 
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chitosan backbone and furthermore maintain pristine amine groups, which are essential for the 
antimicrobial activity of chitosan. The use of D­AAs isomers to functionalize chitosan seems to 
improve the antibacterial properties compared to the pristine chitosan or to the use of the L­AAs. 
However, further investigations, such as PCA experiments, are necessary to draw more definitive 
conclusions on the influence of such stereoisomers on the antimicrobial activity of chitosan. 
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6. Final remarks and outlooks 
Chitosan is an interesting and multi­functional material and can be used for many different scopes 
and applications, e.g. as coating agent for antimicrobial surfaces or as encapsulating agent. The 
substitution of chitosan with thiol­bearing substituents could significantly increase the 
antibacterial properties of pristine chitosan. The new compounds, i. e. chitosan thiomers, are 
worthy to be investigated further against other different pathogens. The encapsulation of the 
POMs with chitosan and its derivative CMC does not have a uniform effect, being able to either 
reduce or enhance the toxicity of the pristine POMs on cancer and normal cells. Further 
investigations on the different cytotoxicity of the isomers of the POM {P2W18} are necessary to 
understand the mechanism behind the increased cytotoxicity of the isomeric mixture compared 
to the pure α­isomer of {P2W18}. A rewarding and interesting research project could involve the 
investigation of chitosan thiomers as encapsulating agents for POMs and the study of their 
biological properties against cancer cells and bacteria. Further mechanistic studies should be 
conducted on the feasibility of the two selective cancer targeting approaches proposed in this 
thesis. The investigation of the antibacterial properties of new functionalized chitosan derivatives 
and of the anticancer properties of POM­chitosan­based nanocomposites performed in this thesis 
paved the way for the preparation of new versatile and efficient drug prototypes.  
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Summary 
Bacteria are posing an increasingly serious threat to human health due to their more and more 
frequent resistance to conventional antibiotics. Infections caused by antibiotic resistant bacteria 
are on the rise worldwide and raising the costs in health care systems. A possible way to overcome 
the dangerous infections caused by antibiotic resistant bacteria is the development of new 
tunable antibacterial drugs which arise from sustainable sources and can be quickly adapted to 
different strains.  
Chitosan is a biopolymer consisting of N­acetyl­D­glucosamine and β­1,4­linked­D­glucosamine 
with well­known antimicrobial properties. Recently, the versatile antimicrobial properties of 
chitosan functionalized with thioglycolic acid (chitosan­TGA) were investigated in our group. To 
further explore and enhance their antibacterial properties, several chitosan thiomers were 
prepared and tested for antimicrobial activity (Chapter 2). Chitosan was functionalized with 
several thiol bearing compounds via amide bond formation activated by the carbodiimide EDC. 
The substituents were mainly alkyl­chain thiomers, such as TGA, thiolactic acid, 
mercaptopropionic acid (MPA), 2­methyl­3­sulfanylpropanoic acid, mercaptobutyric acid, 
mercaptohexanoic acid and mercaptooctanoic acid. Moreover, chitosan was functionalized with 
cysteine, mercaptobenzoic acid and 2­iminothiolane. Four chitosan sources with different 
degrees of deacetylation DD (87­94%) and molecular weight MW (18­250 kDa) were used as 
starting materials, and their influence on the antimicrobial activity of the functionalized 
derivatives was investigated.  
Some issues were encountered in the synthesis of chitosan thiomers activated by EDC. The DS of 
the chitosan­TGA, synthesized according to the original procedure, were lower than expected. 
Several attempts to increase the DS of chitosan­TGA were made (Chapter 4) through applying and 
modifying several published procedures. Formation of a Schiff base between chitosan and 
mercaptoacetaldehyde and the reaction of chitosan with the TGA acyl chloride were also tested. 
While the DS could be increased compared to the initial attempts, MTT tests on Escherichia coli
revealed that highly substituted chitosan­TGA did not enhance the antibacterial activity. 
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Structure­activity relationships between the functionalization of chitosan and the antimicrobial 
effect was investigated with comprehensive analytical characterization of the polymers (Chapter 
2). Special emphasis was placed on the determination of DD, MW and degree of substitution (DS). 
Chitosan thiomers were characterized by 1H­NMR spectroscopy, gel permeation chromatography, 
elemental analysis, Ellman test, ζ­potential measurements and FT­IR spectroscopy. The DD and 
MW strongly depended on the starting material, while the DS was influenced by the 
functionalizing reagent. The well­known MTT assay was adapted and applied for a fast and 
reliable screening of the antimicrobial properties of the newly synthesized derivatives. 
The antimicrobial activity of the thiomers was tested on two gram­negative strains, E. coli and 
Pseudomonas aeruginosa, and on two gram­positive strains, Streptococcus sobrinus and
Streptococcus mutans. MTT results showed superior efficacy of the derivatives produced from 
chitosan 85/20 (MW  90 kDa and DD  93%), probably due to the higher DD. Moreover, a high 
DS decreased the antibacterial activity, which may be linked to the lower amount of available 
amine groups. Furthermore, the antimicrobial activity of chitosan functionalized with the D­ and 
L­isomers of cysteine and alanine, respectively, was tested by MTT on E. coli. Surprisingly, the 
D­isomers exhibited superior antibacterial properties (Chapter 5). 
The antimicrobial properties of the most promising alkyl thiol substituted chitosans, synthesized 
from chitosan 85/20, were further investigated by plate counting. Plate counting is a quantitative 
and reliable method which permits the detection of very few surviving bacterial cells. Under the 
applied experimental conditions E. coli was scarcely affected by the treatment of alkyl thiomers. 
On the other hand, chitosan alkyl thiomers led to a reduction of the bacterial population by a 
factor of 5 log or more for P. aeruginosa, S. sobrinus and S. mutans. In particular, at least one 
chitosan thiomer per strain was able to completely eradicate the bacterial population. Chitosan­
MPA was selected as representative example to perform a LIVE/DEAD assay that confirmed the 
antibacterial action evidenced by the PCA experiments. The above investigation emphasizes the 
outstanding antimicrobial properties of N­acyl thiolated chitosans and paves the way to the 
design of new highly efficient, biocompatible and cost­effective antimicrobial compounds. 
Cancer is becoming progressively a curable disease through the continuous improvement of 
innovative therapies and early diagnosis. However, cancer treatments often remain highly 
expensive and may pose financial issues to many patients worldwide. Polyoxometalates (POMs) 
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are discrete, negatively charged polyoxoclusters composed mainly of molybdenum, tungsten and 
vanadium metal centers in their highest oxidation states. Over the past decades, POMs were 
proposed and frequently investigated in vitro as promising inexpensive candidates for new 
antidiabetic, antiviral, antibacterial and anticancer drugs. However, their clinical applications 
remain to be explored, because their selectivity, toxicity and stability at physiological conditions 
needs to be controlled individually. A promising approach to reduce their cytotoxicity, while 
enhancing their selectivity towards biological targets is their encapsulation into biocompatible 
polymeric matrices and drug carriers, such as chitosan and its derivatives. 
In this work {Sb9W21}, {Mo7O24} and {P2W18} were selected as known promising candidates for 
medical applications, and their nanocomposites with chitosan and carboxymethyl chitosan (CMC) 
were newly prepared. Chitosan and CMC were selected in order to cover the entire pH range: 
chitosan is soluble at pH < 6.5 and CMC at pH > 7. The overall goal was to investigate the change 
in cytotoxicity of POMs upon encapsulation in a biocompatible matrix on bacteria and somatic 
cells (Chapter 3). 
{Sb9W21} as a proven antiviral POM and {P2W18} were synthesized according to the reported 
procedures and extensively characterized by single­crystal XRD, powder­XRD, elemental analysis 
and FT­IR spectroscopy. Additionally, 31P­NMR spectroscopy was applied to characterize {P2W18}. 
These techniques confirmed the identity and the phase purity of the compounds. {P2W18} was 
prepared as α­isomer and as a mixture of the α­, β­ and γ­isomers. 
POM­chitosan nanocomposites were prepared through cross­linking interaction between the 
positively charged chitosan and the negatively charged POMs under constant sonication. In 
comparison, POM­CMC nanoparticles were prepared under constant stirring while applying Ca2+
(from CaCl2) as cationic cross­linker between the negatively charged CMC and POM. The 
nanocomposites were characterized with dynamic light scattering (DLS) and electron microscopy 
(SEM and TEM) to determine their size range (100­200 nm) and morphology. The morphology 
observed was partially dependent on the composition of the nanocomposites and on the 
methodology used for sample preparation.  
Moreover, the stability of POMs and of nanocomposites under physiological conditions was 
addressed as a key issue for future applications. The encapsulation improved the stability of the 
otherwise unstable {Sb9W21} and did not alter significantly the stability of {P2W18}.  
Summary 
131 
The cytotoxicity of the pristine POMs as well as of the nanocomposites was evaluated against 
bacteria (gram­positive S. sobrinus and gram­negative E. coli) as well as on mammalian cell lines, 
namely HeLa and MRC­5. {Sb9W21} and {P2W18} and their as­prepared nanocomposites did not 
show any particular antibacterial activity, thus highlighting their possible use in bacteria­friendly 
applications, where the local flora should not be harmed during the treatment. {Mo7O24} showed 
low cytotoxicity against both the tested cell lines, while α­{P2W18} and {Sb9W21} were more toxic. 
Surprisingly, the isomeric mixture of α­, β­, and γ­{P2W18} exhibited higher cytotoxicity compared 
to the pure α­isomer. Furthermore, the cytotoxicity of (TBA)4[Mo8O26], K7[PTi2W10O40], 
K4[SiMo12O40] and (NH4)6[P2Mo18O62], and of the nanocomposites with chitosan or CMC was 
preliminary tested on HeLa cells.  
The modification of cytotoxicity of pristine POMs upon encapsulation was not univocal: the 
cytotoxicity of the nanocomposite could be either increased or reduced, depending on the POM 
and the polymeric matrix. Furthermore, the tested cell line plays a role in determining the 
cytotoxicity. In view of these results the cytotoxicity of POM­chitosan and POM­CMC 
nanocomposites should be always evaluated individually. 
Two possible ways for selective targeting against cancer cells were proposed, based on the pH 
dependent stability of chitosan and CMC nanoparticles. The first approach involves POMs whose 
toxicity is increased upon chitosan encapsulation (e.g. {Mo7O24}). POM­chitosan nanoparticles are 
stable at the acidic pH of cancer tissue, so that they could eliminate cancer cells upon local 
injection. When POM­chitosan nanoparticles diffuse toward the healthy tissue (pH 7.2­7.3), the 
polymer would precipitate and may eventually impair the transport of nutrients to the cancerous 
area. The pristine POM may be gradually released from the chitosan nanoparticle, after enzymatic 
degradation of the polymer. The separated components would be present in the healthy tissue 
at low, presumably non­cytotoxic concentrations and be cleared by the organism. The second 
approach to target the cancer cells involves POM­CMC nanoparticles with low toxicity on normal 
cells compared to the pristine POM (e.g. {P2W18}), that could be injected into the bloodstream. 
Due to their size below 200 nm and their negative surface charge, POM­CMC nanoparticles may 
accumulate in the cancer tissue due to the EPR effect. Furthermore, at the acidic pH of cancer 
cells the POM­CMC nanoparticles precipitate and they could release the POM at cytotoxic 
concentration after enzymatic degradation, thereby eliminating the cancer cells. Further in vitro
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and in vivo experiments are necessary to verify the feasibility of the two proposed targeting 
approaches and to confirm the applicability of POM­chitosan and POM­CMC nanocomposites as 
pH sensitive drugs. 
The cytotoxicity data collected so far highlight the difficulties in predicting the biological activity 
of POM­chitosan­based nanocomposites. Substantial research to underpin the structure­activity 
relationships of these composites is now required. The investigation of the antibacterial 
properties of new functionalized chitosan derivatives and the anticancer properties of POM­
chitosan­based nanocomposites performed in this thesis paves the way for the preparation of 
new versatile and efficient drug prototypes.  
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Zusammenfassung 
Bakterien, die zunehmende Resistenz gegen die herkömmlichen Antibiotika entwickeln, werden 
zu einer ernsthaften Bedrohung für die menschliche Gesundheit. Die Zunahme der Infektionen 
durch antimikrobiell resistente Bakterien verursacht weltweit steigende Kosten für die 
Gesundheitssysteme. Ein möglicher Ansatz dieses Problem zu bekämpfen ist die Entwicklung von 
neuen Antibiotika. 
Das Biopolymer Chitosan ist bekannt für seine antimikrobiellen Eigenschaften und besteht aus 
β­1,4­glykosidisch verknüpften N­Acetyl­D­glucosamin Einheiten. Vor kurzem begann unsere 
Gruppe mit der Erforschung der antimikrobiellen Eigenschaften von Chitosan, das mit 
Thioglykolsäure (Chitosan­TGA) funktionalisiert wurde. Zum besseren Verständnis der 
antibakteriellen Eigenschaften von Chitosan Derivaten wurden mehrere thiolierte Chitosane 
synthetisiert und auf ihre antimikrobielle Aktivität getestet (Kapitel 2). Dazu wurde die 
Aminogruppe von vier Chitosanpolymeren, die sich im Deacetylierungs­Grad (Englisch: degree of 
deacetylation, DD, 87­94%) und Molekulargewicht (MW, 18­250 kDa) unterscheiden, durch 
Carbodiimide (EDC) aktiviert, um mit Thiolen eine Amidbindung einzugehen. Für die 
Funktionalisierung der Biopolymere wurden Thiole mit unterschiedlich langen Alkylketten 
verwendet (TGA, Thiomilchsäure, 3­Mercatoproprionsäure (MPA), 
2­Methyl­3­mercaptopropionsäure, 4­Mercaptobutansäure, 6­Mercaptohexansäure und 
8­Mercaptooctansäure). Zudem wurde Chitosan mit Cystein, 4­Mercaptobenzoesäure und 
2­Iminothiolan funktionalisiert.  
Die Synthese von thioliertem Chitosan, aktiviert durch EDC, ging einher mit einigen 
Schwierigkeiten. Der Substitutionsgrad (Englisch: degree of substitution, DS) des Chitosan­TGA, 
synthetisiert nach dem Verfahren aus der Literatur, war niedriger als erwartet. Mehrere Versuche 
zur Erhöhung des DS von Chitosan­TGA wurden durchgeführt (Kapitel 4). Dabei wurden 
publizierte Verfahren wiederholt und angepasst. Die Bildung einer Schiff’schen Base zwischen 
Chitosan und Mercaptoacetaldehyden und die Reaktion von Chitosan mit dem TGA­Acylchlorid 
wurden ebenfalls durchgeführt. Der DS konnte in Bezug auf die ersten Versuche erhöht werden. 
Der MTT­Test mit E. coli ergab allerdings, dass stark substituierten Chitosan­TGA Proben keine 
höhere antibakterielle Aktivität zeigten. 
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Die Beziehung zwischen Struktur und Aktivität funktionalisierter Chitosan­Derivate und deren 
antimikrobieller Wirkung wurde umfassend untersucht. Besonderen Wert wurde auf die 
Bestimmung von DD, MW und Substitutionsgrad (DS) gelegt. Gesamthaft wurden 
1H­NMR­Spektroskopie, Size­Exclusion­Chromatographie, Elementaranalyse, Ellman­Test, 
ζ­Potential Messungen und FT­IR­Spektroskopie zur Charakterisierung der Biopolymere 
verwendet. Während DD und MW allein vom Ausgangsmaterial abhängen, wird der 
Substitutionsgrad von dem funktionalisierenden Reagenz bestimmt. 
Die antimikrobielle Aktivität der Biopolymere wurde an zwei Gram­negativen Bakterienstämmen 
(Escherichia coli und Pseudomonas aeruginosa) und zwei Gram­positiven Stämmen (Streptcoccus 
sobrinus und Streptococcus mutans) getestet. Der MTT Assay wurde auf die jeweiligen Bakterien 
angepasst und soweit optimiert, dass eine schnelle und zuverlässige Überprüfung der 
antimikrobiellen Eigenschaften der neu synthetisierten Derivate durchgeführt werden konnten. 
Die MTT Testresultate zeigten eine überlegene Wirksamkeit der Derivate aus Chitosan 85/20 
(MW  90 kDa und DD  93%). Weiter konnte gezeigt werden, dass ein hoher DS die 
antibakterielle Aktivität verringert. Dies kann durch die geringere Menge an verfügbaren 
Aminogruppen erklärt werden. Darüber hinaus wurde die antimikrobielle Aktivität von Chitosan 
mit dem D­und L­Isomer von Cystein und Alanin durch MTT­Tests mit E. coli getestet. 
Überraschenderweise zeigten die D­Isomere überlegene antibakterielle Eigenschaften (Kapitel 5). 
Die antimikrobiellen Eigenschaften der vielversprechendsten Derivate, hergestellt aus Chitosan 
85/20, wurden durch das Auszählen von Bakterienkolonien auf Inkubationsplatten (PCA) noch 
genauer studiert. PCA ist eine zuverlässige Methode, die es erlaubt, auch wenige überlebende 
Bakterienzellen zu erkennen. Die thiolierten Chitosane hatten in unseren Experimenten kaum 
eine Wirkung auf E. coli. Bei den anderen Bakterienstämmen (P. aeruginosa, S. sobrinus und
S. mutans) wurde hingegen eine Verringerung der bakteriellen Population von mindestens 5 log 
Einheiten beobachtet. Für alle drei Bakterienstämme wurde jeweils ein thioliertes 
Chitosan­Derivat gefunden, dass die Bakterienpopulation vollständig auslöschen konnte.  
Die bakterizide Wirkung wurde zusätzlich am repräsentativen Beispiel von Chitosan­MPA in 
Live/Dead Assays überprüft. Die Testresultate bestätigten die Beobachtungen aus dem 
PCA­Experiment. Die durchgeführten Versuche unterstreichen die hervorragenden 
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antimikrobiellen Eigenschaften von N­Acylthiolierten Chitosan­Derivaten und ebnen den Weg für 
die Entwicklung von neuen, hocheffizienten, biokompatiblen und kostengünstigen 
antimikrobiellen Verbindungen. 
Krebs wird dank früher Diagnosen und innovativer Therapien zunehmend zu einer heilbaren 
Erkrankung. Allerdings sind Krebsbehandlungen sehr teuer und für einen grossen Teil der 
Weltbevölkerung daher oft erschwert zugänglich. Polyoxometallate (POMs) sind diskrete, negativ 
geladene Metall­Sauerstoff­Cluster, die vorwiegend aus Molybdän, Wolfram und Vanadium in 
ihren höheren Oxidationszuständen bestehen. POMs wurden als vielversprechende Kandidaten 
für neue Medikamente gegen virale und bakterielle Infektionen, Diabetes und Krebs 
vorgeschlagen. Die klinische Anwendung von POMs ist allerdings noch zu erforschen, da die 
Selektivität, Toxizität und Stabilität dieser Verbindungen unter physiologischen Bedingungen 
individuell angepasst werden muss. Eine Möglichkeit ihre Zytotoxizität zu reduzieren und 
gleichzeitige die Selektivität für biologische Ziele zu verbessern ist ihre Einkapselung in eine 
biokompatible Polymer­Matrix, wie zum Beispiel Chitosan. 
In dieser Arbeit wurden die POMs {Sb9W21}, {Mo7O24} und {P2W18} als vielversprechende 
Kandidaten für medizinische Anwendungen ausgewählt und mit Chitosan und Carboxymethyl 
Chitosan (CMC) eingekapselt. Chitosan und CMC wurden ausgewählt, da diese beiden 
Biopolymere einen breiten pH­Bereich abzudecken vermögen: Chitosan ist bei pH­Werten < 6.5 
löslich, während CMC bei pH­Werten > 7 löslich ist. Anhand dieser Strategie wurde die 
Veränderung der Zytotoxizität von POMs nach der Einkapselung in eine bioverträgliche Matrix mit 
Bakterien und somatischen Zellen untersucht (Kapitel 3). 
Die Cluster {Sb9W21} und {P2W18} wurden wie in der Literatur beschrieben synthetisiert und 
ausführlich durch die Röntgenstruktur­Analyse von Einkristallen und mit 
Röntgen­Pulvermethoden sowie FT­IR­Spektroskopie charakterisiert. Zusätzlich wurde {P2W18} 
mit 31P­NMR­Spektroskopie untersucht. Alle Analysen bestätigten die Identität und die 
Phasenreinheit der Verbindungen. Das POM {P2W18} wurde als α­Isomer und als Gemisch aus den 
α­, β­, γ­Isomeren hergestellt. 
Die POM­Chitosan­Nanopartikel wurden durch cross­linking zwischen dem positiv geladenen 
Chitosan und dem negativ geladenen POMs im Ultraschallbad vorbereitet. Die 
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POM­CMC­Nanopartikel wurden unter ständigem Rühren und der Verwendung von Ca2+ (aus 
CaCl2) als kationisches Quervernetzungsmittel hergestellt. Die Grösse (100­200 nm) und 
Morphologie der Nanopartikel wurden durch dynamische Lichtstreuung (DLS) und 
Elektronenmikroskopie (SEM und TEM) bestimmt. Die beobachtete Morphologie war einerseits 
abhängig von der Zusammensetzung der Nanopartikel und andererseits von der angewandten 
Methode für die Probenpräparation.  
Darüber hinaus wurde die Stabilität von POMs und Nanopartikeln unter physiologischen 
Bedingungen als ein zentrales Thema für zukünftige Anwendungen untersucht. Die Einkapselung 
verbesserte die Stabilität des labilen {Sb9W21}, hatte aber keinen wesentlichen Einfluss auf die 
Stabilität von {P2W18}. 
Die Zytotoxizität der unbehandelten POMs sowie der Nanopartikel wurde auf Bakterien (dem 
Gram­positiven Stamm S. sobrinus und dem Gram­negativen Stamm E. coli) sowie auf 
Säugetierzelllinien, namentlich HeLa und MRC­5, überprüft. 
Die POMs {Sb9W21} und {P2W18} sowie die hergestellten Kompositen zeigten keine besondere 
antibakterielle Aktivität, weshalb sich diese Verbindungen besonders für die Verwendung in 
bakterienfreundlichen Anwendungen eignen, bei denen die örtliche Flora während der 
Behandlung nicht geschädigt werden sollte. 
Der Cluster {Mo7O24} zeigte eine niedrige Zytotoxizität gegen die beiden getesteten Zelllinien, 
während α­{P2W18} und {Sb9W21} giftiger waren. Überraschenderweise zeigte die α­, β­ and 
γ­Isomerenmischung {P2W18} eine höhere Zytotoxizität als das α­Isomer. 
Darüber hinaus wurden die Zytotoxizität der Cluster (TBA)4[Mo8O26], K7[PTi2W10O40], 
K4[SiMo12O40] und (NH4)6[P2Mo18O62] und ihrer Nanokomposite mit Chitosan oder CMC auf HeLa­
Zellen in ersten Experimenten getestet. Bei Vergleich der Zytotoxizität der reinen POMs mit den 
eingekapselten POMs konnte kein eindeutiger Trend festgestellt werden: die Zytotoxizität des 
Nanopartikels konnte je nach POM und Polymermatrix entweder erhöht oder reduziert werden. 
Darüber hinaus spielten die getesteten Zelllinien eine Rolle bei der Bestimmung der Zytotoxizität. 
Zwei Möglichkeiten zur selektiven Behandlung von Krebszellen wurden vorgeschlagen, basierend 
auf der pH­abhängigen Stabilität von Chitosan­ und CMC­Nanopartikeln. Der erste Ansatz 
beinhaltet POMs, deren Toxizität bei Einkapselung in Chitosan erhöht wird (e.g. {Mo7O24}). 
POM­Chitosan­Nanopartikel, die im sauren pH­Milieu der Krebszellen stabil sind, könnten bei 
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lokaler Injektion die Krebszellen eliminieren. POM­Chitosan­Nanopartikel würden dann in 
Richtung des gesunden Gewebes diffundieren (pH 7.2­7.3), wo das Polymer den Transport von 
Nährstoffen zum Krebsgewebe beeinträchtigen würde. Das reine POM würde nach dem 
enzymatischen Abbau des Polymers nach und nach aus den Chitosan­Nanopartikeln freigesetzt. 
Die beiden getrennten Komponenten lägen im gesunden Gewebe dann in nicht­toxischen 
Konzentrationen vor und würden durch den Organismus ausgeschieden werden. 
Der zweite Ansatz zur Bekämpfung der Krebszellen beinhaltet POM­CMC­Nanopartikel mit 
geringer Toxizität gegenüber normalen Zellen im Vergleich zu den reinen POMs (e.g. {P2W18}), die 
in den Blutstrom injiziert werden könnte. Aufgrund ihrer Größe unter 200 nm und ihrer negativen 
Oberflächenladung könnten sich POM­CMC­Nanopartikel aufgrund des EPR­Effekts im 
Krebsgewebe ansammeln. Darüber hinaus würden diese Komposite im sauren Milieu der 
Krebszellen ausfallen, wobei dann nach enzymatischem Abbau die POMs freigesetzt und eine 
lokale cytotoxische Wirkung auf die Krebszellen entfalten würden. 
Weitere in vitro­und in vivo­Experimente sind nun notwendig, um die Realisierbarkeit der beiden 
vorgeschlagenen Targeting­Ansätze zu überprüfen und POM­Chitosan und POM­CMC­Komposite 
als pH­sensitive Medikamente zu bestätigen. 
Die bisher gesammelten Zytotoxizitäts­Daten unterstreichen die Schwierigkeit, die biologische 
Aktivität von POM­Chitosan­basierten Kompositen vorherzusagen. Umfangreiche 
Forschungsarbeiten zur Etablierung der zugrundeliegenden Struktur­Aktivitäts­Beziehungen sind 
nun erforderlich. Die Untersuchungen zu antibakteriellen Eigenschaften von neuen 
funktionalisierten Chitosan­Derivaten und zu krebstherapeutischen Eigenschaften von 
POM­Chitosan­basierten Kompositen in dieser Arbeit ebnen den Weg für die Entwicklung neuer, 
vielseitiger und effizienter Wirkstoff­Prototypen. 
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